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ABSTRACT 
INVESTIGATIONS OF N-ACETYLTRANSFERASES IN 
HUMAN HEPATOCYTES AND RAT MODELS 
Jason M. Walraven 
March 4, 2005 
This thesis begins by reviewing human N-acetyItransferases (Chapter I), then outlines 
experiments involving human hepatocytes and rat N-acetyltransferases (Chapters II-V). These 
experiments facilitated the development of a dissertation project designed to study N-
acetyltransferase tissue-specific expression in inbred rat strains (Chapter VI). 
Real-time PCR experiments concluded that genetic and/or environmental factors 
influence N-acetyItransferase expression in cryopreserved human hepatocytes. Therefore, an 
animal model must be used to study N-acetyItransferase expression. Initial studies of 
recombinantly expressed rat N-acetyltransferases (Nats) revealed a correlation between rat and 
human N-acetyltransferases in nucleotide and amino acid sequence, catalytic activity, substrate 
selectivity and thermostability, suggesting the rat is an acceptable model for such studies. 
Dissertation aims outlined for studying rat N-acetyltransferase expression in tissues of various 
inbred rat strains involve analysis of tissue-specific mRNA splicing, mRNA expression, protein 
expression, and enzyme activity, and a study of cigarette smoke inhalation as a possible 
environmental influence on Nat expression. 
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CHAPTER I 
BACKGROUND AND SIGNIFICANCE 
Arylamine N-acetyltransferases NATI and NAT2 are xenobiotic metabolizing enzymes 
that first received attention over 40 years ago when researchers discovered that polymorphic 
NAT2 modifies individual human variability in the metabolism of the anti-tubercular drug 
isoniazid (Evans et aI., t 960; Peters et aI., 1965), making N-acetyltransferases among the first 
polymorphic genes identified. It was later discovered that this role extended also to other 
hydrazine drugs including the MAO inhibitor phenelzine and the anti-hypertensive drug 
hydralazine (Lemke et aI., 1995; Weber and Hein, 1985). NATs also detoxify the antibacterial 
sulfonamides (Parker, t 969) and arylamine drugs such as the antiarrhythmic drug procainamide, 
the antibiotic dapsone, and the aromatase inhibitor aminoglutethimide (Weber and Hein, 1985) 
(Figure 1). 
The human genome encodes two active N-acetyltransferase isoforms, NAT! and NAT2, 
each consisting of a single intronless coding exon 870 base pairs long. These genes lie in close 
proximity on chromosome 8 (Matas et aI. 1997), with high nucleotide sequence identity (86.8%), 
and which encode proteins that share a high amino acid sequence identity (80.0%). Human 
NAT 1 and NAT2 enzymes are very similar in their sequence and function, with distinct, yet 
overlapping, substrate selectivities, distinct structural stabilities, and distinct kinetic properties 
toward their arylamine substrates (Blum et aI., 1990; Hein et ai, 1993). 
In addition to drug detoxification, NATs are implicated as modifiers of cancer 
predisposition due to their roles in both detoxification and activation of aromatic and heterocyclic 























Figure 1. Chemical Structures of Some N-acetyltransferase Substrates. 
N-acetyltransferase (NAT) isozymes metabolize aromatic amines, heterocyclic amines, and 
hydrazines, including many pharmaceutical drugs and environmental carcinogens. (A) Some 
pharmaceutical drugs metabolized by NATs include the antitubercular drug isoniazid, the antihypertensive 
drug hydralazine, the MAO inhibitor phenelzine, the aromatase inhibitor aminoglutethimide, the antibiotic 
dapsone, the antiarrhythmic drug procainamide, and the antibacterial drug sulfamethazine. (B) Some 
environmental carcinogens metabolized by NATs include 4-aminobiphenyl (ABP), a component of 
cigarette smoke, and 2-amino-I-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), found in meats cooked 
well-done. 
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4-aminobiphenyl (ABP), a component of cigarette smoke (Patrianakos et aI., 1979), the 
carcinogen 2-amino-l-methyl-6-phenylimidazo[ 4,5-b ]pyridine (PhIP), and other protein pyrolysis 
products, formed in meats cooked well-done (Godshalk et aI., 2001; Layton et aI., 1995). Prior to 
acting as mutagens and animal carcinogens, these compounds must first undergo metabolic 
activation by xenobiotic metabolizing enzymes (Wogan et aI., 2004). 
N-acetyltransferases catalyze N-acetylation (usually detoxification), O-acetylation 
(activation), and N,O-acetylation (activation) reactions (Hein DW, 1988). These reactions are 
carried out via a ping-pong reaction mechanism in which the NAT enzymes use acetyl-CoA as 
the acetyl-group donor (Riddle and Jencks, 1971). All N -acetyitransferases, regardless of species, 
contain the Cys-His-Asp catalytic triad, which resembles that of cysteine proteases (Sinclair et aI., 
2000). NATs catalyze N-acetylation (Figure 2) by transferring an acetyl group from acetyl-CoA 
to the exocyclic nitrogen of an aromatic or heterocyclic amine. This is usually a detoxification 
step, leading to excretion of the metabolite. For O-acetylation (Figure 2) to take place, the 
exocyclic amine must first undergo N-hydroxylation by a CYPIAI or CYP1A2 enzyme. This 
reaction competes with N-acetylation for the exocyclic nitrogen, and is considered an activation 
step. N-acetyitransferases will further activate the carcinogen by transferring an acetyl group to 
the oxygen. The resulting N-acetoxy metabolite is very unstable and spontaneously decomposes 
to acetic acid and a highly reactive arylnitrenium ion. This electrophilic ion will then form 
adducts with nucleophilic sites throughout the ceil, including DNA and proteins. N,O-acetylation 
(Figure 2) is similar to O-acetylation except that the competing N-acetylation and N-
hydroxylation reactions both succeed, result in an N-acetylated and N-hydroxylated exocyclic 
nitrogen. NATs can then catalyze intramolecular O-acetylation, resulting in the same unstable 
acetoxy species formed by O-acetylation (Hein DW, 1988). 
Because NAT! and NAT2 are highly polymorphic, they contribute to individual cancer 
susceptibility by modifying the activation and deactivation of arylamine carcinogens. To date, 
over 25 known human NAT! alleles and over 35 known human NAT2 aIIeIes have been identified, 
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Figure 2. Reactions Catalyzed by Arylamine N-acetyltransferases 
o-o-~ f ~ ~ ,p N-O-C - - 'CH 
] 
N-Acetoxy-ABP 
N-acetylation occurs when an acetyl group is transferred from acetyl-CoA to the exocyclic 
nitrogen of an aromatic or heterocyclic amine, and is usually a detoxification step. P450 enzymes compete 
with NATs for metabolism of the exocyclic nitrogen where they catalyzing a hydroxylation reaction, 
thereby activating the carcinogen. NATs can further activate the compound by subsequently acetylating 
the oxygen which results in an extremely unstable N-acetoxy derivative. The N-acetoxy form of the 
molecule spontaneously breaks down to form an electrophilic arylnitrenium ion which can form adducts 
with DNA and other nucleophilic sites in the cell. Alternatively, the exocyclic nitrogen can be both N-
acetylated and N-hydroxylated, in which case NATs will catalyze an intramolecular transfer of the acetyl 
group to the oxygen, resulting in formation of the reactive arylnitrenium ion. 
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each of which possess a combination of single nucleotide polymorphisms (SNPs) (Vatsis et aI., 
1995). Some of these SNPs modify the acetylator phenotype of an individual by altering enzyme 
stability, enzyme function, and/or mRNA expression, resulting in rapid, intermediate, and slow 
acetylator phenotypes (Butcher et ai., 2002; Fretland et ai., 2001 alb; Leff et ai., 1999a; Zang et 
aI., 2004). The fact that these enzymes are highly polymorphic makes them a prime research 
subject for molecular epidemiology studies, from which we can gain insight into how different 
allelic forms of these enzymes can modify an individual's cancer risk, drug response, and the 
susceptibility to adverse drug reactions (Rein et ai., 2000b; Spielberg, 1996). While the 
xenobiotic metabolizing function of NATs applies to pharmaceutical drugs and carcinogens, as 
covered above, this review will focus on the role of NATs in carcinogen metabolism and cancer 
susceptibility. 
Molecular epidemiology studies that have investigated the relationship between N-
acetyltransferase genotype/phenotype and cancer risk suggest that NATs modify predisposition to 
various cancers. Such studies have investigated the role of polymorphic NAT variants in urinary 
bladder cancer (Cartwright et aI., 1982; Lower et ai., 1979), colorectal cancer (Bell et ai., 1995a; 
Chen et ai., 1998), breast cancer (Bulovskaya et ai., 1978; Millikan et ai., 1998), lung cancer 
(Cascorbi et ai., 1996; Bouchardy et aI., 1998), head and neck cancer (Gonzalez et aI., 1998; 
Olshan et aI., 1997), prostate cancer (Fukutome et ai, 1999; Wade1ius et ai., 1999), pancreatic 
cancer (Bartsch et ai., 1998), and others. Some of these studies suggest a positive correlation 
between certain NAT genotypes and predisposition to cancer. In general, however, the findings 
of these epidemiological studies are inconsistent. Apparent inconsistencies may be attributable to 
the study of different chemical carcinogens, inadequate understanding of the genotype/phenotype 
relationship of some alleles, small sample size, and/or other confounding factors not accounted 
for in the study design (Rein et ai., 2000a). The most consistently reported molecular 
epidemiological associations indicate that individuals with a NAT2 slow acetylator phenotype are 
at higher risk for urinary bladder cancer (Cartwright et ai., 1982; Lower et ai., 1979), due to 
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decreased detoxification (N-acetylation) of aromatic amines, and individuals with a NAT2 rapid 
acetylator phenotype have an elevated risk for developing colon cancer (Gil and Lechner, 1998; 
Ilett et aI., 1987), due to increased activation (O-acetylation) of heterocyclic amines. While we 
know little about the role of NATl and NAT2 in cancer susceptibility, we know less about the role 
of NAT! (Hein, 2002). This lack of understanding regarding NAT! could be due to an incomplete 
understanding of the relationship between NAT! genotype and phenotype, and the factors that 
influence this relationship (Hughes et aI., 1998; Butcher et aI., 1998). Although such ambiguity is 
observed for some NAT2 alleles, it is to a lesser extent than for NA T! (Gross et aI., 1999; Meisel 
et aI., 2001; Sim et aI., 2000). 
The epidemiological observation that NAT influence on cancer risk varies depending on 
tissue type, as mentioned above, could be explained in various ways. One possible explanation 
worth considering involves the tissue-specific regulation of NAT isozymes. This could easily 
account for the differences in susceptibility of different tissues to NAT2-mediated carcinogenesis. 
Tissue-specific expression could be key to the physiological function of N-acetyltransferases, and 
therefore also an important factor influencing the ability of physicians to predict tissue-specific 
cancer risk following aromatic amine exposure. NAT! and NAT2 tissue-specific expression could 
play an important role in arylarnine-induced cancer risk by determining the ratio of inactive to 
reactive arylarnine metabolites within each cell (Grant et aI., 2000), thus modifying the risk of 
mutagenesis. 
The relative expression of NATI and NAT2 in different tissues is important because 
NATI and NAT2, while similar in many ways, differ in several important aspects. First, NATI 
and NAT2 have different substrate preferences (Hein et aI., 1994; Minchin et aI., 1992; Wild et 
aI., 1995). Although there is some overlap, most substrates are preferentially metabolized by one 
isozyme over the other. For instance, human NATl selectively acetylates p-aminobenzoic acid 
(PABA), whereas human NAT2 selectively acetylates sulfamethazine (SMZ) (Grant et aI., 1991). 
Substrate selectivity is influenced by three key residues in the NAT genes, at positions 125, 127, 
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and 129, all three of which differ between NATI and NAT2 (Goodfellow et aI., 2000). Since 
NAT 1 is catalytically more efficient than NA T2 (Grant et aI., 1997; Vatsis et aI., 1995; Vatsis and 
Weber., 1997), the pool of activated or deactivated carcinogens in a tissue following any given 
arylamine exposure is dependent on whether NATl or NAT2 or both are expressed and active in 
that tissue, and at what level they are expressed. For example, a high-NAT I-expressing tissue 
with barely detectable NAT2 expression may be more at risk from exposure to a NATI selective 
carcinogen than a NAT2 selective carcinogen. In addition to substrate selectivity, NATI and 
NAT2 differ in structural stability, where NAT2 is much more stable than NATI (Dupret et aI., 
1994). This difference, detected experimentally as thermostability, could translate into 
differences in cellular enzyme turnover. Lastly, differential expression of NAT I and NAT2 in 
tissues is important because the catalytic efficiency of the enzymes differs, where NAT I 
generally catalyzes reactions much more efficiently than NAT2 (Grant et aI., 2000). Therefore, 
considering the differences between NATI and NAT2 in substrate selectivity, structural stability, 
and catalytic activity, the tissue-specific expression of these isozymes must be better understood 
if we are to advance our understanding of NAT -mediated cancer risk in vivo. 
Tissue-specific gene expression is common in the human genome (Bulun et aI., 2003; 
Shmelkov et aI., 2004; Simpson, 2004; Whetstine et aI., 2002), and therefore it is reasonable to 
suspect that N-acetyltransferase expression might be regulated likewise. While apparent tissue-
selective epidemiological associations could be explained away by alternative hypotheses, other 
data lend support to the idea that NATI and NAT2 are tissue-specifically and cell-type-
specifically expressed, though mRNA and protein expression analyses in a wide range of tissues 
have yielded inconsistent results (Hickman et aI., 1998). 
Unfortunately, NAT protein expression analyses and NAT mRNA expression analyses 
have not produced consistent conclusions regarding the sites of NATI and NAT2 expression. 
Analyses of NAT protein activity in tissues conclude that NATI is ubiquitously expressed 
(Pompeo et aI., 2002; Rodrigues-Lima et aI., 2003), while NAT2 expression is limited to liver 
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(Evans and White, 1964) and intestinal epithelium (Hickman et ai., 1998). On the other hand, 
NATl and NAT2 transcripts were detected in most tissues using in situ hybridization (Debiec-
Rychter et ai., 1999; Windmill et aI., 1997), suggesting that both NA Tl and NAT2 mRNA are 
ubiquitously expressed. Several factors contribute to the apparent discrepancies between analyses 
of protein and mRNA expression. 
First, mRNA detection methods and protein detection methods differ with regard to 
sensitivity. In situ hybridization is a highly sensitive technique capable of detecting even low 
levels of transcript (Wilson et ai., 1997), while measurements of enzyme activity are generally 
less sensitive. Thus, NATl and NAT2 mRNA are more readily detected than the NATI and 
NAT2 enzyme activity. 
Second, flaws in experimental design may produce false and confusing results. Correct 
probe design is crucial for accurate mRNA detection. This point becomes apparent when 
considering the example of conflicting intestine NAT expression reports. It was concluded based 
on NAT enzyme acetylation activity measurements that NATl is expressed higher than NAT2 in 
the intestine (Hickman et aI, 1998), while mRNA expression analysis suggested that NAT2 is 
expressed even higher than NATl (Windmill et aI., 1997). A careful examination of the methods 
reveals that the NATI probes were designed to target to a DNA sequence 5' of the NATl start 
codon, which is a sequence that may not exist in most NATl transcripts. Although this 5' 
sequence comes from a previously reported NATl transcript (Ohsako and Deguchi, 1990), its 
presence in NATl mRNA transcripts is questionable. Recent analyses of NATl promoters 
(Butcher et aI., 2004b; Husain et ai., 2004) do not report this transcript as having even a minor 
presence among NATl transcripts. Perhaps NATl expression only appears to be lower than NAT2 
expression in Windmill's mRNA staudy because the NATl probe recognizes only small fraction 
of NAT I transcripts at best. 
A final factor deserving consideration regarding discrepancies between protein and 
mRNA expression measurements involves the often difficult and/or misleading interpretation of 
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NATI and NAT2 enzyme activity data. For instance, in muscle NAT2 mRNA was detected but 
NAT2 enzyme activity was below the limit of detection; on the other hand, NATl mRNA enzyme 
were readily detected (Rodrigues-Lima et aI., 2003). Detection of NAT! enzyme but not NAT2 
enzyme could be attributed to higher NATI catalytic activity for its selective substrates as 
compared to that of NAT2 for its selective substrates. This would permit detection of lower 
levels of NAT I by enzymatic activity measurements than similarly low levels of NAT2 (Grant et 
aI., 2000). Detection of low enzyme levels using activity assays is problematic, requiring 
relatively high enzymatic activity. In the example above from muscle tissues, the NAT2 activity 
level may have fallen below the detection limit, due to its relatively low activity. 
The lack of consistent data regarding the tissue-specific expression of NATl and NAT2 
precludes coming to meaningful conclusions about how NA Tl and NAT2 are expressed in the 
different tissues of the body. A more practical approach must be devised. Understanding how 
NAT mRNA expression, protein expression, and enzyme activity are regulated has value for 
advancing our understanding of how NA T I and NAT2 tissue-specific expression relates to NA T I 
and NAT2 phenotype in different tissues. Analyzing only one of these factors alone, however, has 
little practical value. Due to the possibility that post-transcriptional regulation events modify 
NAT expression, NA Tl and NAT2 mRNA levels cannot be used as an accurate predictor of NAT 
phenotype in a tissue. Likewise, due to the possibility that post-translational regulation events 
modify NAT expression, NATl and NAT2 protein levels cannot be used as an accurate predictor 
of NAT phenotype in a tissue (since it may be that not all NAT protein is active). Also, it is 
possible that these forms of regulation vary widely from tissue to tissue and cell-type to cell-type, 
so that it is faulty to assume that the relative levels mRNA expression, protein expression, and 
enzyme activity will be in the same proportion in different tissues. Aside from the method 
difficulties discussed above, the fundamental weakness of the studies to-date with regard to their 
ability to contribute useful information regarding NAT tissue-specific expression is the mistake of 
analyzing only one measure of NAT expression at a time. No study reported to date provides 
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concrete data regarding how NATl and NAT2 tissue-specific expression influences NAT 
phenotype in tissues because no study to date has analyzed NAT mRNA, protein, and enzyme 
activity concurrently in different tissues. This type of study is needed for a more complete 
picture of the translational, transcriptional and post-transcriptional influences on NATl and NAT2 
expression, and how they might vary among different tissues. 
Recent analyses of NATl mRNA structure, and continued studies of NAT induction 
suggest that NATl expression is transcriptionally regulated. (Butcher et aI., 2003; Boukouvala et 
aI., 2003; Mitchell and Warshawsky, 2003; Zaher and Svensson, 1994). Identification and 
characterization of the major NATl promoters and non-coding exons in human breast 
demonstrated the presence of at least 4 alternative NATl promoters (Butcher et aI., 2004b; Husain 
et aI., 2004), which could be key to the mechanism by which NAT tissue-specific expression is 
regulated (Boukouvala et aI., 2003; Rodrigues-Lima and Dupret, 2004). These studies have also 
demonstrated that alternative splicing of the 9 NATl non-coding exons results in at least 7 
different mRNA species, with a single dominant promoter in breast tissue. Many mammalian 
genes are tissue-specifically expressed through promoter-dependent alternative splicing of non-
coding exons, resulting in multiple mRNA species with different transcriptional and translational 
efficiencies (Bulun et aI., 2003; Shmelkov et aI., 2004; Ayoubi and Van De Ven, 1996; Whetstine 
et al. 2002). Since our knowledge of NATl mRNA structure and expression is limited to a single 
tissue in humans (breast), much work remains to be done for other tissues. Also, much remains to 
be delineated with regard to these possible expression mechanisms, requiring further study of 
NAT] and NAT2 promoter usage and mRNA splicing patterns in multiple tissues. In addition to 
an advanced understanding of NAT expression, promoter analyses may provide a foundation for 
discovery of an endogenous role for N-acetyltransferases by providing links to biomolecular 
signaling pathways involved in NAT expression. 
Inconsistent molecular epidemiology data regarding the association of NATl and NAT2 
genotype and cancer risk, combined with an unclear relationship between NATl genotype and 
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phenotype suggest that our understanding of the factors (other than NAT! and NAT2 SNPs) that 
influence acetylator phenotype is incomplete. Environmental and other genetic factors may 
influence acetylator phenotype and arylamine-induced cancer risk (Butcher et aI., 2000b; Husain 
et aI., 2004). Advancing our understanding of NAT-mediated cancer risk through successful 
molecular epidemiology investigations requires consideration of these other possible influences 
on NAT I and NAT2 tissue-specific expression. 
The literature reviewed above suggests that these factors probably influence NAT I 
expression nearly exclusively, considering the observed divergence of NAT! genotype and 
phenotype, and the consistent NAT2 genotype and phenotype correlations. Some have postulated 
that the apparent lack of correlation between NA T! genotype and phenotype is due to an 
incomplete knowledge of NAT! polymorphisms, which would be resolved once a more 
comprehensive list of NA T! polymorphisms is compiled (Payton and Sim, 1998). Others suggest 
that endogenous compounds or NAT substrates and/or products influence NATl expression 
(Butcher et aI., 2000a/b; Ward et aI., 1992). Yet others propose the possibility that NAT activity 
and expression are influenced by non-genetic, or environmental factors (Butcher et aI., 1998). 
While we don't completely understand NAT regulation outside of SNPs and genotype, it is clear 
that in vivo N-acetyltransferase phenotype is influenced by genetic and environmental factors 
independently of known NAT genotype (Rodrigues-Lima and Dupret, 2004). 
Genetic influences on gene expression include cis-acting and trans-acting genetic factors 
(Morley et aI., 2004). Unknown linked, or cis-acting, genetic factors could include unidentified 
genetic polymorphisms in NAT I and NAT2 promoters or other control regions that influence NAT 
expression. Such SNPs could alter transcription initiation and/or efficiency, or affect mRNA 
processing, folding, and/or stability. For example, a mutation in the promoter of the low-density 
lipoprotein receptor gene identified in a familial hypercholesterolemia patient caused an 80% 
reduction of the promoter activity (Mozas et aI., 2002). While cis-acting genetic factors account 
for up to 35% of the variability in gene expression among individuals, trans-acting loci have an 
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even greater influence on variability in gene expression throughout the genome (Pastinen and 
Hudson, 2004). Unlinked, or trans-acting, genetic factors are variable among individuals due to 
the uniqueness of their genetic backgrounds. These factors include polymorphic genes outside 
the NAT J and NAT2 loci that influence their expression, such as transcription factors or other 
expression control proteins. The function of trans-acting genes could vary among individuals as a 
result of SNPs or other function-affecting factors that influence their expression and/or activity. 
The expression of HMG-CoA reductase provides an example of this type of gene regulation. 
HMG-CoA reductase expression in mouse liver is about 5-fold higher in C57BLl6 mice than 
BALB/c mice. Cis-acting genetic factors affecting the structural gene were ruled out as a cause 
for this tissue-specific variation of HMG-CoA reductase mRNA expression, and a trans-acting 
locus that controls the gene's expression was found to be the determining factor (Hwa et aI., 
1992). Both cis-and trans-acting genetic factors should be seriously considered for their possible 
role in regulating the expression of N-acetyltransferases, and NATl in particular. 
In addition to genetic influences on NAT expression, environmental stimuli may 
influence NAT expression. Environmental influences may include occupation-related and/or 
lifestyle-related factors such as cigarette smoke or exposure to industrial chemicals. Experiments 
in cell culture have shown that NAT expression is influenced by external stimuli such as 
curcumin, a spice (Chen et aI., 2003), the anticancer drug paclitaxel (Yang et aI, 2003), luteolin, a 
compound found in many common edibles such as celery and peppermint (Su et aI., 2003), even 
Vitamin C (Hung and Lu, 2001) and acetaminophen (Roth en et aI., 1998). These influences act 
to induce or inhibit NAT mRNA expression and/or enzyme activity in the cell culture systems 
tested. Other cell culture experiments suggest that NAT substrates (p-aminobenzoic acid, p-
aminosalicylic acid, ethyl-p-aminobenzoate, and p-aminophenol) down-regulate NATI activity 
by down-regulating NATl protein, while mRNA remained unchanged (Butcher et aI., 2000b). In 
similar studies, hydroxylamine-PABA irreversibly inactivated NAT 1 though covalent 
modification of the enzyme active site (Butcher et aI., 2000a). Inactivation of NATl enzymes by 
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their substrates and other xenobiotics may also take place at the level of transcription VIa 
xenobiotic-inducible regions on NATI and NAT2 promoters (Mitchell and Warshawsky, 2003). 
Other studies suggest substrate-dependent post-translational inactivation via substrate-induced 
conversion of the NAT 1 active site from a stable acetylated state to an unstable deacetylated state, 
thereby leaving the active site cysteine unprotected and resulting in the ubiquitination and 
subsequent degradation of the NATI enzyme (Butcher et aI., 2004a). Oxidative stress and 
cellular redox stress may also influence NAT 1 activity. Reactive oxygen species (ROS), such as 
hydrogen peroxide, can inactivate NATI by reacting with its active site cysteine. This results in a 
sulfenic acid form that is reversible by reducing agents such as reduced glutathione (Atmane et 
aI., 2003). Reactive nitrogen species (RNS), such as S-nitrosothiols, also inhibit the NAT! 
enzyme by targeting and modifying the reactive cysteine at its active site, resulting in a mixed 
disulfide, a reaction that is also reversible in the presence of reducing agents (Dairou et aI., 2003). 
Pathophysiological processes such as inflammation produce the highly reactive RNS 
peroxynitrite that reacts with the active site cysteine to form sulfonic and sulfinic acids which, 
unlike hydrogen peroxide and S-nitrosothiols, irreversibly inactivates NAT 1 (Dairou et aI., 2004). 
UVB irradiation is an oxidative process that induces inactivation of NAT 1 and NAT2 in human 
lens epithelial cells, also a reversible reaction (Dairou et aI., 2005). Overall, these studies have 
shown that NAT! activity and/or expression is/are influenced by non-genetic factors such as 
pharmaceutical drugs, environmental chemicals, cellular oxidants, and even inflammation-related 
chemicals. More investigations are needed into assess the importance of these environmental 
variables on N-acetyltransferase expression in an animal model. Further characterization of these 
influences may aid in resolving the NATl genotype/phenotype inconsistencies and clarify NATl 
molecular epidemiology data (Rodrigues-Lima and Dupret, 2004). 
Some potentially important questions regarding the influence of genotype and 
environment on NAT expression may help shape future investigations NATl and NAT2 tissue-
specific expression. Can environmental exposures or unknown cis- or trans-acting genetic factors 
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overwhelm the influence of an individual's NAT] and/or NAT2 genotype? Are genetic factors 
(cis- and/or trans-acting factors, and tissue-specific expression) the primary determinants of NATl 
and NAT2 acetylator phenotype, or do environmental exposures also influence acetylator 
phenotype? Do environmental exposures and trans-genetic factors influence the expression of 
NATl and NAT2 equally, or is one locus more sensitive to certain regulatory influences than the 
other locus? The answers to these questions are important for understanding how NAT-mediated 
individual predisposition to certain cancers is modified in individuals by better understanding the 
factors that influence interindividual expression of NATl and NAT2. 
How NAT] and NAT2 are tissue-specific expressed, and the genetic and environmental 
influences on that expression, are thus far unknown. The lack of basic information regarding 
NAT promoters and other expression control regions has precluded the search for cis-acting 
mutations outside the coding region until lately. Recent identification of human NATl promoters 
(Husain et aI., 2004) and the promise of the same for NAT2 (Husain et aI., 2003) should speed the 
discovery of functionally significant polymorphisms in expression control regions (cis-acting 
genetic factors). A great deal of work remains to be done if we are to understanding N-
acetyltransferase tissue-specific expression and the environment and trans-acting genetic 
influences that modify that expression. 
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CHAPTER II 
NAT! EXPRESSION IN PRIMARY HUMAN HEPATOCYTES 
Introduction 
Cryopreserved human hepatocytes are an ideal system for analyzing genotype/phenotype 
relationships. The advantages of primary cell culture, the ability to work with a single cell type 
that has not been altered through an immortalization process (Li et aI., 1999; Sun et aI., 1993), 
and the convenience of cryopreserved samples that are conveniently accessed at will, are 
combined into one with cryopreserved hepatocytes. Since the liver is a key site for xenobiotic 
metabolism, and both NAT! and NAT2 are expressed in liver (Windmill et aI., 2000), hepatocytes 
are suitable for studying N-acetyltransferase expression. 
Our lab obtained 76 cryopreserved human hepatocyte samples, representing as many individuals 
(In vitro Technologies, Inc., Baltimore, MD, USA). These hepatocytes were genotyped for NAT! 
and NAT2 by real-time RT -PCR using previously published methods (Doll and Hein, 2001; Doll 
and Hein, 2002). The same samples were then tested for NAT 1 and NAT2 N-acetylation activity 
using p-aminobenzoic acid (PABA) as the selective substrate for human NAT! (Doll et aI., 
1997), and sulfamethazine (SMZ) as the selective substrate for human NAT2 (Leff et aI., 1999b). 
The results indicated that NAT! acetylator phenotype did not correlate with expected NAT! 
phenotype, as deduced from NAT! genotype (Figure 3A). In fact, the acetylation rates varied 
over 600-fold among NAT!*4/*4 individuals (n = 38) and over 350-fold among NAT! *4/*10 
individuals (n = 24). The data for NAT!*IO/lO individuals were tighter, but the sample size was 
much smaller (n = 4). The NAT2 data, on the other hand, demonstrated a clear correlation 
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Figure 3. Cryopreserved Hepatocyte NATl and NAT2 GenotypeIPhenotype Correlation 
Cryopreserved hepatocytes were genotyped for NAT] and NAT2, then tested for NAT I and NAT2 
N-acetylation activity using NATI-selective substrate p-aminobenzoic acid (PABA), and NAT2-selective 
substrate sulfamethazine (SMZ). Activities were grouped according to genotype and plotted as shown 
above. (A) NA Tl *4 is the wild-type allele, and NA Tl *] 0 is a variant allele that demonstrates higher 
activity than NATl*4 in vitro (Badawi et aI., 1995; Bell et aI., 1995b). NAT]*41*4 homozygotes and 
NATl*41*JO heterozygotes demonstrate a wide range ofN-acetylation activities_ (B) NAT2*4 is the wild-
type rapid allele, and NAT2*5 and NAT2*6 alleles are slow alleles. Combining rapid NAT2*4 with a 
NAT2*5 or NAT2*6 allele results in intermediate phenotype. Genotyping and enzyme activity assays were 
performed by Mark Doll. 
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genotype (Figure 3B). 
This is not the first time this phenomenon has been observed for NAT]. Other studies 
have documented a lack of correlation between NA T] genotype and phenotype in placenta (Smelt 
et aI., 1998), breast (Williams et aI., 200 I), and whole blood (Payton and Sim, 1998). Possible 
reasons for this discrepancy between NA Tl genotype and expected acetylator phenotype could 
include the following: (I) the existence of unidentified cis-acting genetic factors, such as 
polymorphisms in NATl expression control regions; (2) environmental influences on NAT] 
expression; (3) variability in trans-acting genetic factors among individuals who have distinct 
genetic backgrounds. These factors were discussed in Chapter I. 
It is clear from Figure 3 that factors other than NAT] genotype influence NATI acetylator 
phenotype in hepatocytes, as in the other tissue types mentioned above. The background data for 
the individuals from whom the hepatocytes originated is not sufficiently detailed to draw 
correlations between environmental exposures and NATl expression. Due to the complexity of 
biological interactions with the environment, it is doubtful whether such correlations are possible 
even with the most detailed background information. Since one cannot experimentally analyze 
the hepatocytes to determine environmental influences on NATl phenotype, the focus must be 
shifted to genetic influences. 
As already mentioned, some have suggested that this problem might be solved following 
more thorough characterization of NA Tl polymorphisms (Payton and Sim, 1998). If unknown 5'-
UTR SNPs influence NAT] expression, characterization of these SNPs may bridge the gap 
between NAT] genotype and phenotype. Since the entire NAT] gene is at least 12 kb long 
(Husain et aI., 2004), sequencing this entire region in a large number of individuals to find 
polymorphisms in this region is practically impossible. Therefore, a different approach is 
necessary. 
While many SNPs may exist in the NA Tl 5' -UTR, polymorphisms of interest are those 
that have functional consequences for NATl expression. Functional consequences of coding 
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region SNPs can be detected as alterations of enzyme activity. Functional SNPs in the 5' -UTR 
can only be detected at the level of mRNA transcription and possibly protein translation. The 
fundamental strategy for the experiments described in this chapter is based on the former. 
Experiments were designed based on competing hypotheses. The first hypothesis is that 
the dramatic variation in human hepatocyte NATl PABA activity within each genotype is the 
result primarily of cis-acting SNPs in the 5' -UTR of the NATl locus. If the data support this 
hypothesis, functionally important mutations exist in the 5' -UTR, providing compelling evidence 
to justify future investigations that analyze the NATl locus for unknown SNPs. The alternative 
hypothesis is that dramatic variation in human hepatocyte NATI PABA activity is not caused 
primarily by genetic differences among individuals at the NATl locus. If the data support the 
alternative hypothesis, environmental or trans-acting genetic factors (genetic variability outside 
the NATllocus) influence NATl expression, warranting further investigation into the influence of 
these factors. 
SNPs in the 5' -UTR could directly alter transcription activity by affecting interactions 
between transcription factors and the NATl promoter, by altering exon splicing patterns, altering 
mRNA structure, etc. Polymorphisms in the 5' -UTR could be as far away as 12 kb or more from 
the NA Tl coding region. Due to genetic recombination by crossing over, these polymorphisms 
could recombine independently of the NATl coding region. In this case, specific 5'-UTR SNPs 
would not associate with specific NATl alleles, but would be distributed randomly among all 
known NATl alleles. For example, two individuals may have the same NATl allele, say 
NATl*41*4, but have different polymorphisms in the 5'-UTR of the NATl gene, resulting in 
drastically different acetylator phenotypes. The complexity of the interactions between 5' -UTR 
polymorphisms and NA Tl alleles would depend on the number of 5' -UTR polymorphisms in the 
population and how drastically they influenced activity (we are only interested in functionally 
important polymorphisms). The experiments described in this chapter were designed based on 
these ideas. 
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The strategy implemented to test the competing hypotheses involves analysis of the 
hepatocytes for functionally important polymorphisms by testing for differences in transcription. 
Since NATl genotypes will harbor unknown 5' -UTR polymorphisms if the first hypothesis is 
true, it is necessary to measure the expression level of NATl alleles independently to determine 
whether the alleles are influenced by some unknown difference that causes them to express at 
different levels. Significant allelic expression differences will be indicative of unknown function-
altering polymorphisms that result in different mRNA transcription rates. Since the first 
hypothesis requires very large mRNA expression differences in order to account for the very 
large variability in enzyme activity, the allelic expression differences will not be subtle and 
therefore identification should be straightforward. 
The above strategy requires measurement of NATl alleles independently. NATl 
genotypes among the hepatocyte were mostly combinations NATl*4 and NATl*1O alleles, with a 
large portion of these NA Tl *41* 10 heterozygotes. Since differences cannot be measured in 
homozygous individuals, the NATl *41*10 hepatocytes are ideal for this type of analysis. Since 
the 5' -UTR polymorphisms are far enough away from the coding region to be recombined 
independently of one another, it is reasonable to think that 5' -UTR polymorphisms will be spread 
among all NATI alleles. With NATl*4 as the reference allele, NATI*1O has polymorphisms 
T\088A and C\095A in the 3'-UTR within the first poly-adenylation signal. These SNPs make 
NA Tl * J 0 alleles distinguishable from NA Tl *4 alleles by the sequence recognition techniques 
described in the methods section. Comparing NATl*1O and NATl*4 mRNA expression in 
NATl*41*JO heterozygous hepatocytes will reveal whether polymorphisms in the 5'-UTR result 
in different versions of the NA Tl *4 and NA Tl * 10 alleles that have drastically different 





Seventy-six cryopreserved hepatocyte samples were obtained from In Vitro 
Technologies, Inc. (Baltimore, MD) and stored in liquid nitrogen upon arrival. Due to limited 
sample availability following other analyses on these hepatocytes, 17 of the 24 original 
NATl *41* 10 heterozygote hepatocyte samples were available for analysis at the time of this 
experiment. The NAT I enzymatic activities of these 17 hepatocytes varied over 350-fold and 
therefore included samples with a representative range of enzyme activities. 
Determination of Method Sensitivity 
Prior to analyzing hepatocyte NATl*4 and NATl*1O expression by real-time RT-PCR, it 
was necessary to test the method's ability to accurately detect differences in NATl*4 and 
NATl*1O mRNA expression. Analysis of a sample with equal amounts of NATl*4 and NATl*lO 
mRNA should give aBele ratio of 1.0. However, this value may deviate from 1.0 due to the 
characteristic sensitivity of the real-time PCR method, instrumentation, and differences between 
the NATl*4 and NATl*lO mRNA probes in their annealing and cleavage (by polymerase) 
efficiencies. Therefore, standards were necessary to determine the range of values surrounding 
1.0 that should be considered as indicative of a 1.0 aBele ratio. Anything outside of this range is 
considered significantly different from 1.0, and is indicative of a real difference in expression 
between the NA Tl *4 and NATl * 10 aBeles. This type of analysis requires a standard guaranteed 
to have equal amounts of NATl*4 and NATl*1O DNA sequence. Genomic DNA is the ideal 
standard since, by definition, genomic DNA from heterozygous individuals contains equal copies 
of each aBele. In theory, NATl*41*1O heterozygous hepatocyte genomic DNA samples should 
have a T~CT value of 1.0 for the ratio of NATl*4 to NATl*IO. 
Genomic DNA from 8 different NATl*4INATl*lO heterozygous individuals was used as 
template for real-time PCR analysis (Figure 4). The reaction mixture contained NATl-specific 
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Figure 4. Real·Time PCR of NATl*4 and NATl*JO eDNA 
The region of cDNA containing the single nucleotide polymorphisms (SNPs) is amplified using 
gene-specific primers. Fluorogenic TaqMan probes complementary to the sequence being detected anneal 
to the specific PCR products as they are created, allowing real·time detection of specific peR products. 
TaqMan probes have a tluorogenic reporter dye on the 5' end and a quencher on the 3' end. The quencher 
reduces the fluorescent signal of the reporter dye by fluorescence resonance energy transfer (FRET). After 
the probe anneals to the specific target sequence, the 5' nuclease activity of AmpliTaq Gold polymerase 
cleaves the probe and separates the quenchcr from the reporter dye, resulting in an increase in fluorescence 
reading. The probe is cleaved as the polymerase extends the target sequence so that peR extension of the 
target sequence is not interrupted. 
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-aacca-3') (Applied Biosystems, Foster City, CA), FAM-Iabelled NATl*4-specific (5'-
atctttaaaagacatttattattatta-3') and VIC-labelled NATl * JO-specific (5' -catctttaaaatacattttttattatta-3 ') 
fluorogenic TaqMan probes (Applied Biosystems), hepatocyte genomic DNA and TaqMan 
Universal PCR Master Mix (Applied Biosystems), which contains AmpliTaq Gold polymerase. 
Real-time PCR was performed using an ABI Prism 7700 sequence detection system from Applied 
Biosystems. The reaction conditions were identical to the conditions used for genotyping the 
hepatocyte samples. These conditions, in addition to the primer and probe design, were described 
previously (Doll and Hein, 2002). 
Allele-Specific Expression in Hepatocyte Samples 
Cryopreserved hepatocytes were thawed on ice, then pelleted according to the 
manufacturer's instructions, and homogenized using QIAshredder columns from Qiagen 
(Valencia, CA). RNA was isolated using the RNeasy Kit from Qiagen, and then separated by 
electrophoresis on a 1% agarose gel to test the RNA quality by observing the distinct 28S and 
18S ribosomal RNA bands. RNA samples were then treated with DNase using the Turbo DNase 
kit from Ambion (Austin, TX) and stored at -80°C. RNA was quantified by separating the RNA 
by electrophoresis on a 1% agarose gel along with RNA standards in known amounts (200 ng, 
400 ng, 800 ng). RNA concentration was determined by densitometric analysis based on the 
standard curve. RNA samples were reverse transcribed using SuperScript III First-Strand 
Synthesis System for RT-PCR from Invitrogen (Carlsbad, CA). Control reverse transcription 
reactions were also performed in the absence of reverse transcriptase as controls for DNA 
contamination. All hepatocyte samples were analyzed for B-actin expression as a normalizing 
control. Real-time PCR was performed on the hepatocyte cDNA samples, as described above for 
the genomic DNA samples. 
Standard Curve for Allele-Specific Measurements 
A standard curve was designed for further analysis of the allelic expressIon data. 
Whereas the real-time PCR primers used for amplifying NATl*4 and NATl*JO are identical, the 
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allele-specific probes are different for NA Tl *4 and NA Tl * 10, and therefore can introduce 
variability. The standard curve will take into account that variability and allow comparison of the 
allele ratios minus the influence of the probe differences. 
Hepatocyte genomic DNAs from NATl*41*4 homozygotes and NATl*lOI*1O 
homozygotes were mixed in NATl*41*4:NATl*101*10 ratios of 100:0, 90:10, 70:30, 50:50, 
30:70, 10:90, and 0: 100 to mimic situations in which the NA Tl *4 and NA T 1 * 10 alleles are 
expressed in different ratios in the hepatocyte samples. These standards were designed to test the 
ability of the method to detect differences in the expression of NATl*4 and NATl*1O alleles, as 
well as to provide a standard curve with which to analyze allele-specific expression. These 
mixtures were analyzed by real-time PCR and data were analyzed in the same way as the 
genomic DNA controls. 
Data Analyses 
NAT 1 data were normalized to ~-actin by subtracting the ~-actin CT value from the 
NA T1 CT value, give the LlCT value. The expression of NA Tl *4 and NAT 1 * 10 alleles in these 
samples were analyzed as the ratio of NATl*4 mRNA to NATl*1O mRNA (NATl*4INATl*IO). 
In the case of equal expression, the ratio equals 1.0; in the case of 2-fold higher NAT 1 *4 than 
NAT 1 * 1 0, the ratio equals 2.0, etc. Therefore, the ratio of the NAT 1 *4 LlCT to the NAT 1 * 1 0 LlCT 
gives the MCT value. Since CT values are inversely proportional to the amount of mRNA 
expressed, it is necessary to normalize to a calibrator, resulting in 2-MC, (calculations derived 
from Applied Biosystems' "User Bulletin #2: ABI Prism 7700 Sequence Detection System," 
2001). This value is mathematically equivalent to the ratio of individual NATl*4 to NATl*1O 2-
"'CT values. For real-time PCR of genomic DNA samples, the value 2-"'CT was calculated, since 
genomic DNA was normalized to DNA concentration and not to an internal standard. This value 
is equivalent to the ratio of NA Tl *4 to NAT 1 * 10 2-CT values. 
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Statistical Analyses 
All assays were performed in triplicate, with each replicate performed on a different day, 
and the standard error of the means (SEM) calculated for the set of triplicate experiments. 
Analysis of variance (ANOV A) was used to determine differences among the allele expression 
ratios for the 17 hepatocyte samples. 
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Results & Discussion 
Determination of Method Sensitivity 
Analysis of heterozygous NA Tl *41* 10 hepatocyte genomic DNA by real-time peR 
resulted in ratios ranging from approximately 0.5 to 1.5 (Figure 5). Therefore, when measuring 
NATl*4 and NATl*1O expression in heterozygous hepatocytes, any allele ratio between 0.5 and 
1.5 will not be considered as different than 1.0. Any ratio less than 0.5 or greater than 1.5 can be 
considered different from 1.0, indicating that the alleles are expressed differently. 
As is evident from the relatively wide range of ratios considered equal to 1.0 (0.5 - 1.5) 
this method is not sensitive enough to detect small differences in allele expression. The method 
is, however, sufficiently sensitive to detect large differences. Explaining the 350-fold range of 
enzyme activities in the NA Tl *41* 10 hepatocytes in terms of cis-acting genetic polymorph isms 
requires that the hepatocytes with the lowest activity possess a combination of very low 
expressing NA Tl *4 and NA Tl * 10 alleles. Likewise, the hepatocytes with the highest activity 
possess a combination of higher expressing NATl *4 and NA Tl * 10 alleles. If this theory is true, 
the low expressing and high expressing alleles represented in these samples must have drastically 
different expression rates. Therefore, although a greater sensitivity might be achieved by 
optimizing the method, the differences in NATl*4 and NATl*1O allele expression that we are 
trying to detect are very large, eliminating the need for a more sensitive method. 
Allele-Specific Expression in Hepatocyte Samples 
The ratios of NA Tl *4 to NAT 1* 10 in 17 hepatocyte samples varied from approximately 
0.5 to 3.3 (Figure 6). Five of these samples show significantly reduced NATl * 10 expression 
relative to NATl*4. The other 12 hepatocyte samples have allele expression ratios that fall within 
the range of 0.5 - 1.5, and thus are not considered different than 1.0. Analysis of variance 
(ANOV A) was performed on the data in Figure 6 showing that the data in this group are 
significantly different (P = 0.014). 
Instead of a random distribution of high expressing and low expressing alleles, the data 
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Figure 5. Quautitative Real-Time RT-PCR Sensitivity for NAT! Allele Expression Analysis 
Heterozygous NATl*4INAT1*1O human hepatocyte genomic DNA samples were analyzed by 
real-time peR. The experimentally determined ratios plotted above, have variability extending about 50% 
above and below (dashed lines) the theoretically expected 1.0 ratio (solid line). Thus, due to the sensitivity 
of the method, experimentally determined NATl *4 and NATl * 10 allele expression ratios below 0.5 or 
above 1.5 will be considered different from 1.0, while anything within this range falls within the limits of 
detection for this method. 
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Figure 6. Relative NAT1 Allele Expression in NATl*41* 10 Human Hepatocytes 
Hepatocyte cDNA samples reverse transcribed from hepatocyte RNA were analyzed for NA Tl *4 
and NATl*1O allele-specific expression by real-time peR. The NATl*4INATl*10 allele expression ratios 
are displayed above. The solid line corresponds to a theoretical NATl *4INATl * 10 expression ratio of 1.0. 
The region between the two dotted lines, which lie above and below the solid line, represent the range of 
expression ratios determined to not be different from 1.0 by this method (Figure 5). Several samples 
demonstrate significant variation from 1.0, indicating unequal expression of the NATl*4 and NATl*1O 
alleles. 
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suggest a general trend of higher NA Tl *4 expression than NA Tl *] 0 expression. It is unclear at 
this point, however, whether this trend is real or an artifact of characteristic differences between 
the probes used to detect NAT] *4 and NA Tl * 10 sequences. It could be that, compared to the 
NAT] *] 0 probe, the NAT] *4 probe anneals to its target more readily and/or is cleaved more 
readily by the polymerase. On the other hand, the NAT] *4 probe could lack complete specificity 
for NATl*4, and anneal to NAT] *10 some of the time, thereby artificially boosting the NATl*4 
signal. These factors were tested using a standard curve, as described in the next section. 
The greatest difference between NA Tl *4 and NA Tl * 10 expression observed m the 
hepatocytes is approximately 3-fold. Therefore, there is no evidence to justify a conclusion that 
enzyme activity differences in heterozygotes (350-fold) are solely caused by forms of NATl *4 
and/or NATl * 10 alleles that express differently. However, the evidence of slight allelic 
expression differences (- 3-fold), possibly caused by 5' -UTR polymorphisms, does not rule out 
the possibility that different forms of known NAT] alleles exist or at least contribute to the lack of 
correlation between NAT] genotype and phenotype in hepatocytes. 
The question then remains: what can account for the inability of NATl genotype to 
predict NATl phenotype? Instead of searching for polymorphisms in the 5' -UTR to explain the 
discrepancy, the strategy described here directly tested the critical question of whether differential 
mRNA expression can account for NATl phenotype. Since this study reveals that differential 
mRNA expression cannot, in fact, account for NA T1 phenotype, the expectation that identifying 
and characterizing 5' -UTR polymorphisms will clear up the problem can be set aside. The list of 
explanations for NAT] phenotype has now been narrowed down to the influences of 
environmental factors and/or trans-acting genetic factors on NATl mRNA and/or protein 
expression. 
Total NATl mRNA expression can be calculated by adding the quantitative expression 
values for both NATl *4 and NATl *10 alleles. No correlation can be observed between total 
NATI mRNA and NAT! enzymatic activity levels (Figure 7). This further supports the idea that 
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Figure 7. Hepatocyte NAT! Activity and NAT1 mRNA Expression 
The X-axis of each graph is labeled with hepatocyte sample identification codes. (A) Hepatocyte 
NAT I enzymatic activities were measured using the NATI-selective substrate p-aminobenzoic acid 
(PABA). (B) Total NAT! mRNA expression was determined by calculating the sum of quantitative 
NATl*4 and NATl*JO mRNA expression measurements. Comparison of NAT I enzyme activity and NAT1 
mRNA in order of increasing enzyme activity reveals the lack of correlation between the two. In fact, the 
sample with the lowest enzyme activity has one of the highest levels of NAT] mRNA expression, while the 
sample with the highest enzyme activity has a relatively low NAT] mRNA expression. 
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factors external to the NAT I locus, either genetic or environmental, are influencing NAT I 
acetylator phenotype post-transcriptionally. Possible mechanisms for such influences were 
mentioned in the Chapter I, and therefore will not be discussed here. 
One concern is that the relatively low stability of the NATI enzyme (Dupret et aI., 1994), 
might take some responsibility for the difficulty in correlating NATI genotype to acetylator 
phenotype. However, there is no reason to believe that In Vitro Techologies somehow 
mishandled the samples. It is more likely that In Vitro Technologies has a great deal of 
experience with these samples, and that they were prepared and handled consistently. The same 
reasoning applies to their handling in our lab. The very strong NAT2 genotype/phenotype 
correlations in these same samples provide evidence for this. It is also important to note that the 
lack of correlation between NA T I genotype and phenotype are not novel, but have been observed 
and reported by others in this field as well (Payton and Sim, 1998; Smelt et aI., 1998; Williams et 
aI., 2001), as discussed in Chapter I. 
Standard Curve for Allele-Specific Measurements 
Creating a standard curve and applying the hepatocyte samples to that curve revealed 
information that might otherwise have gone unrealized. The standard curve clarified whether the 
general trend of higher NAT I *4 than NAT I * I 0 expression in the hepatocytes is real or an artifact 
of probe characteristics. Data from real-time PCR of NA Tl *4/*4 and NA Tl * 10/* I 0 genomic 
DNA mixtures were analyzed the same way as the allele-specific expression analyses in the 
previous section. NA Tl *4/NA Tl * I 0 ratios were calculated (this time as T<lCT values, since no 
internal standard is applied) and plotted (Figure 8A). A standard curve was then created by 
fitting a third order polynomial to these points (R2 = 0.98), giving an equation with which the 
hepatocyte allelic expression data could be fitted to the curve (Figure 8B). This curve takes into 
account the differences between the two probes used to recognize NA Tl *4 and NA Tl * I 0 
sequences. The hepatocyte allele expression data were fitted to the curve by substituting the 
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Figure 8. Creation of a Standard Curve with NATl*41*4 & NATl*lOI*lO Genomic DNA Mixtures 
Hepatocyte NATl*41*4 and NATl*lOl*lO genomic DNAs were mixed in various ratios to mimic 
possible expression ratios of NAT] *4 and NATl *10 and analyzed by real-time PCR. (A) The ~CT values 
were plotted instead of the T~CT values, since the ~CT curve gave a polynomial equation that is more 
convenient to use, and graphically easier to read and understand. (B) The ~CT values were then fitted to a 
third-order polynomial curve (equation shown on graph) with very close fit (R2 = 0.98). This curve will be 
the standard curve for analysis of hepatocyte allele expression data relative to genomic DNA standards, and 
the third order polynomial equation will be used to fit these data to the curve. 
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for the "x" variable using the equation solver function of a Texas Instruments TI-86 calculator, 
which equals the value corresponding to the correct NAT 1 *4:NA Tl * 10 mixture. These new data 
were then plotted on the standard curve (Figure 9) along with the genomic DNA samples from 
Figure 5. 
The analysis revealed that the trend of greater NA Tl *4 expression than NAT 1 * 10 
expression is real and not an artifact of the probe differences. When plotted on this standard 
curve using the third order polynomial equation, the genomic DNA samples, which should 
theoretically come to an allele ratio of 1.0, had a mean NATl*4/NATl*lO ratio of approximately 
l.l, or 53% NATl*4 and 48% NATl*1O. This suggests that the NATl*4 and NATl*1O probes act 
differently in this real-time peR method. The hepatocyte allele expression data gave a mean 
NATl*4/NATl*1O ratio of approximately 1.8, or 64/38; this means that 64% of the NAT I mRNA 
was NA Tl *4 and only 38% was NA Tl * 10. Mean allele ratios of the hepatocyte samples and the 
heterozygous genomic DNA samples are significantly different according to at-test (P = 0.0050). 
The difference observed between the NATl*4 and NATl*lO alleles is not unusual in that 
variations in allelic expression are common in the human genome (Shuen Lo et aI., 2003; Yan et 
aI., 2002). On the other hand, an observation of lower NATl*1O mRNA expression than 
reference NATl*4 mRNA expression is unusual in light of reports that NATl*1O is a rapid allele 
with reference to NATl*4 (Badawi et aI., 1995; Bell et aI., 1995b). Since NATl*1O is different 
from NA Tl *4 only outside of the coding region, these NA Tl alleles code for the exact same 
enzyme. Thus, the difference must be transcriptional or translational, and not related to enzyme 
function. These data are apparently inconsistent with reports that bestow rapid allele status on 
NATl*1O relative to NATl*4, but consistent with enzyme activity data from the cryopreserved 
hepatocytes (Figure 3). 
It is, however, unclear from our analysis whether the general trend of low NATl*1O 
mRNA expression compared to NA Tl *4 is a genuine case of allele-specific expression. It is 
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Figure 9. Standard Curve Analysis of Hepatocyte NATl Allelic Expression 
Hepatocyte eDNA ~~CT values, NAT1*41*10 genomic DNA ~CT values, and NAT1*41*4 and 
NA T1 * 101* 10 homozygote genomic DNA ~CT values (controls) were all fitted to the standard curve using 
the third-order polynomial equation that describes the curve (displ ayed above). When the value for "y" is 
inserted into the equation, solving for "x" gives a value corresponding to the NAT1 *4: NATI *IO mixture 
ratio. The mean allele ratio for NAT1 *41*10 genomic DNA standards (blue triangle) gives an 
NA T1 *4:NATI * 10 allele ratio of 53:47. The mean allele ratio for hepatocyte eDNA samples (red triangle) 
gives a NATI *4:NAT1 *10 allele ratio of 64/36. Error bars on either side of these means indicate that the 
standard error of the means (SEM) for these two means do not overlap. A t-test reveals the means are 
significantly different (P = 0.(050). 
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percentage of NA Tl * 10 transcripts by altering the poly-adenylation signal usage. If the first poly-
adenylation signal following the human NATl stop codon were utilized during translation, NATl 
real-time PCR primers would be unable to amplify the necessary segment of that transcript, since 
the primers anneal to sequences on either side of the signal. The T 1088 A SNP in NA Tl * 10 DNA 
sequence changes the thymine to an adenine in the first AATAAA poly-adenylation signal 
following the stop codon. Such a change can have obvious deleterious effects on the use of this 
signal (Sheets et aI., 1990). However, this SNP creates yet another stop codon, where the AAT 
on the 5' end of the original signal become the three 3' adenine nucleotides on a new AATAAA 
signal. 
Instead of increased usage of this new poly-adenylation signal, which would decrease 
detection of NA Tl * 10 transcripts and give reason to question the allele-specific 
NA Tl * 1O/NA Tl *4 expression data, it is expected that the usage of this new signal would decrease 
instead of increase, or at least remain the same. Although the SNP creates a new signal only 3 
nucleotides 5' of the original signal, the optimal distance between the poly-A signal and the site 
where cleavage and poly-adenylation occur has been altered. Data suggest that there is a spatial 
requirement for the distance between the poly-A signal and the actual site of cleavage/poly-
adenylation. Unless this requirement is met, efficient mRNA production may be compromised 
(Nevins, 1983). On the other hand, analyses of mRNA structure using the "Fold" program (Zuker 
and Stiegler, 1981) and "Squiggles" program (Osterburg and Sommer, 1981) suggest that the 
NATl*1O polymorphisms do not alter the mRNA secondary structure (de Leon et aI., 2000), and 
it is therefore believed that the altered poly-A site is well-tolerated. 
Regardless of whether the TlO88 A SNP in the NA Tl * 10 allele creates a less functional 
poly-adenylation signal than the original NATl *4 allele or creates no change at all, there is no 
reason to believe that the T lO88A SNP creates a more functional poly-A signal, resulting in a 
fraction of NAT 1 * 10 transcripts that could not be detected by the real-time PCR method described 
above. The discrepancy still exists, however, between the reduced NAT 1 * 1 0 mRNA expression 
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described in this chapter and the designation of NATJ*JO as a rapid acetylator NATl allele by 
others. Further analyses may determine that the paradox is explained by translational differences 
due to 5'-UTR SNPs associated with the NATl*/o allele specifically. Such analyses are beyond 
the scope of this study and will not be pursued. 
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Conclusions 
Quantitive real-time RT-PCR was used to detect allele-specific expression differences 
with moderate sensitivity. Sequence detection using gene-specific primers and allele-specific 
probes provides the necessary specificity. With some optimization, this method could be 
improved to allow for even greater sensitivity than was required for these experiments. 
Analysis of NAT1*4 and NATl*1O mRNA expression in 17 NATl*41*1O cryopreserved 
human hepatocytes by quantitative real-time RT-PCR provides evidence for cis-acting genetic 
factors that can cause up to 3-fold difference in mRNA expression. While these cis-acting 
genetic factors may contribute to the observed discrepancy between NA Tl genotype and 
phenotype in primary hepatocytes, differences in allele expression alone are not responsible for 
the 350-fold difference in NAT! enzymatic activity in the hepatocytes examined. Fitting the real-
time PCR data to a standard curve reveals possible allele-specific expression of these NA Tl 
alleles; NA Tl * 10 mRNA expression is significantly lower than NAT 1 *4 mRNA expression in the 
NA Tl *41* 10 heterozygotes. This difference in expression appears to be real, and not an artifact 
ofthe method, though more should be done to understand the NA Tl * 10 allele. 
These data point to the conclusion that unknown cis-acting genetic factors, such as NAT 1 
polymorphisms in the 5' -UTR, do not account for the general discrepancy between NATl 
genotype and phenotype in hepatocytes. They also, therefore, provide indirect evidence for the 
influence of environmental factors and/or trans-acting genetic factors on NATl phenotype. 
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Future Experiments 
To test for a correlation between NATI enzyme activity and NAT] protein level, a 
Western blot for should be performed on cytosols from the 17 hepatocyte samples analyzed in 
this study. This experiment will complete the hepatocyte NAT] story and give an indication of 
the role of translational and/or post-translational regulation on NAT! expression in hepatocytes. 
Due to the lack of remaining sample from the 17 individuals represented in this study, more 
hepatocytes from the same individuals will be ordered from In Vitro Technologies. 
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CHAPTER III 
A RODENT MODEL FOR STUDYING N-ACETYLTRANSFERASE TISSUE-SPECIFIC 
EXPRESSION 
Further investigation into NATl and NAT2 tissue-specific expression will require a model 
that accommodates analysis of tissue mRNA and protein expression, and analysis of both genetic 
and environmental influences on their expression. Every experimental model has characteristic 
advantages and disadvantages that should be evaluated based on the purpose of the study and the 
quality of information that the model can provide for completing the aims of the study. 
Since the importance of studying N-acetyltransferases lies primarily in its human 
application, directly studying human tissues and human NAT genes is preferred. However, the 
disadvantages of analyzing human tissues for this type of study far outweigh the benefit. Human 
tissues can be obtained from a variety of sources, including the National Cancer Institute's 
Cooperative Human Tissue Network and the Armed Forces Institute of Pathology National 
Pathology Repository (Eiseman and Haga, 1999). However, the availability of each sample is 
limited and the quantity and quality is variable and unpredictable. In addition, there are no 
guarantees that the tissue section obtained is representative of the whole tissue, which is 
important when comparing tissue-specific expression of multiple individuals. The quality of the 
tissues is questionable since the method and time of tissue collection are often unknown and 
highly variable. Due to possible deleterious effects of mishandling on mRNA and protein 
preservation, tissue quality and the consistency of tissue handling and processing are very 
important when analyzing mRNA and protein expression. Perhaps more importantly, the natural 
variability associated with interindividual human environmental exposures, and the distinct 
genetic backgrounds among humans make human tissues an inappropriate system for studying the 
38 
tissue-specific expression of genes whose expression may be influenced by trans-genetic and 
environmental variables. 
Animal models are the ideal system for studying tissue-specific expression in the absence 
of unpredictable environmental exposures and genetic variability, and they also provide the most 
direct and effective means of studying the influence of genetic variability and environmental 
exposures on gene expression. Mores specifically, the rat model is often used as a system for 
better understanding human gene expression; many gene expression studies in rat are used to 
extrapolate meaningful conclusions about what might also be true for expression of analogous 
human genes (Ariel et aI., 2004; Sigfrid et aI., 2004; Van Tuyl et aI., 2003). 
As is the case with human tissues, use of rat tissues as a model for NATl and NAT2 
expression has advantages and disadvantages. Advantages include the near unlimited availability 
of any tissue of interest, and the freedom to analyze a specific and consistently chosen section of 
tissue (or even the whole tissue) to ensure that expression measurements are consistent and 
representative of the many cell types that make up a tissue. The quality of the tissues that can be 
obtained from an animal model is ideal, since the procedures used for tissue harvesting can be 
kept consistent from sample to sample, and the tissues can be preserved immediately following 
harvest. Other advantages include the controlled environment of animal storage facilities and the 
genetic consistency that can come from using inbred rat strains. These advantages must be 
weighed against a disadvantage, common to any animal model, which is the questionable 
relevance of rat Nats to human NATs. 
The relevance of in vivo rat studies to human NATl and NAT2 could be addressed by 
comparing nucleotide and protein sequences. Both rat and human N-acetyltransferases have a 
single intronless 870 base pair coding region (Matas et al. 1997). Rat and human N-
acetyltransferase genes and enzymes have high sequence identities, as much as 80% amino acid 
sequence identity and 84% nucleotide sequence identity. More importantly, the catalytic triad, 
Cys68-His 107 -Asp 122 (Sinclair et aI., 2000), is identical in rats and humans, thus implying the 
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same catalytic function. The three amino acids that play an important role in determining 
substrate selectivity in human NATI and NAT2 can be compared to rat protein sequences. In 
fact, human NATI and rat Nat2 have the same three amino acids at these sites, Phe 125-Argl 27-
Tyr129, suggesting that they have similar substrate selectivities. Human NAT2 and rat Natl, on 
the other hand, while they share only one identical amino acid, have similarities in their 
sequences with SerI25-SerI27-Ser129 for human NAT2 and Tyr125-SerI27-TyrI29 for rat Nat\. 
This would suggest that rat Nat I and human NAT2 have similar substrate selectivities. Overall, 
gene and protein sequence comparisons suggest that rat and human N-acetyltransferases share the 
same biological functions in vivo. 
Rats could also provide a good in vivo model for rapid and slow N-acetyltransferases 
alleles. While most rats are rapid acetylators (Nat2*20 allele), two rat strains have been 
identified as slow acetylators. Slow Nat2 alleles have been identified in rat strains WKY 
(Nat2*21A) and NSD (Nat2*21B). The Nat2*21A slow allele has the four transitions G361A, 
G399 A, G796 A, and G522 A, while the NAT2 *21 B slow allele has the four transitions G361 A, G399 A, 
G796 A, and C672T (Hein et aI., 1991 a,b; Juberg et aI., 1991). The mechanism by which these 
SNPs confer slow acetylator status is unknown and should be studied further. 
Although sequence similarities are compelling, a correlation between rat and human N-
acetyltransferases must be experimentally determined. This might be accomplished by 
comparing the catalytic properties, substrate selectivity, and structural stability of the rat and 
human N-acetyltransferase enzymes, thereby validating the rat model as a legitimate model for 
studying N-acetyltransferases in vivo. Before this could be done, however, the suspected 
existence of a third functional rat N-acetyltransferase had to be identified (Chapter IV). 
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CHAPTER IV 
IDENTIFICATION, CLONING, AND SEQUENCING OF A NOVEL RAT 
N-ACETYLTRANSFERASE (NATJ) 
Introduction 
N-acetyItransferases are expressed in a wide range of animal species. Certain 
characteristics are conserved across species, including the Cys-His-Asp cysteine protease-like 
catalytic triad and the 870 base pair intronless coding region. Other aspects, however, are highly 
variable, such as the exact coding region nucleotide sequence and even the number of NAT 
isoforms encoded for within the organism's genome. The human genome contains two functional 
N-acetyltransferase genes, NAT] and NAT2, and also an inactive pseudo-gene called NATP (Blum 
et aI., 1990). NATP resembles a human N-acetyItransferase in its nucleotide sequence, and might 
have been an active NAT gene at one time. Other animals, however, have more or fewer N-
acetyltransferase isoforms; mice have three (Kelly and Sim, 1994), cats have only one (Trepanier 
et aI., 1998), and dogs have none (Trepanier et aI., 1997). 
The discovery of murine Nat3 hinted at the existence of a similar third Nat gene in rats. 
This suspicion was confirmed with the appearance of a GenBank entry for "rattus norvegicus 
similar to mouse Nat3" (XM_224762). This potential rat Nat3 sequence was predicted by 
automated computational analysis from an annotated genomic sequence (NW _047470) using a 
gene prediction method called GNOMON (National Center for Biotechnology Information). The 
sequence comes from rat strain BN/SsNHsdlMCW, which is a Brown Norway substrain from 
Harlan Sprague Dawley, Inc., and the Medical College of Wisconsin. 
The validity of the rat as a model for N-acetyltransferase activity and expression could be 
affected by the existence of a third rat N-acetyltransferase gene. If rat Nat3 contributes in large 
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part to acetylator phenotype in rat tissues, the lack of an equivalent human gene could render the 
rat less valid as a model. On the other hand, the third N-acetyltransferase gene could have similar 
properties to the third mouse N-acetyltransferase gene. Mouse Nat3 enzyme has very low 
activity relative to mouse Natl and Nat2 (Estrada-Rodgers et aI., 1998; Fretland et aI., 1997). 
Therefore, the importance of rat Nat3, which is very similar to mouse Nat3 in nucleotide and 




Cloning of the Rat Nat3 Gene 
The rat Nat3 coding region was amplified from Fisher 344, Sprague Dawley, and Wistar 
Kyoto genomic DNA by duplicate independent PCR reactions using Taq polymerase (Perkin 
Elmer Corp., Norwalk, CT, USA). Gene-specific primers were designed using GenBank 
sequence "rattus norvegicus similar to mouse Nat3" (XM_224762). The forward PCR primer has 
sequence 5' -gtagcaIT£gggatggacattgaagcgtactt-3' and contains an Xmaf restriction site 
(underlined) to facilitate cloning. The reverse PCR primer has sequence 5'-
atgcgactgcagctaaatagtaaaaagccaatt-3' and contains a Pstf restriction site (underlined) to facilitate 
cloning. PCR-amplified Nat3 was then ligated into pcDNA3.1 TA cloning vector and 
transformed into TOPIO competent E.coli using a TA Cloning Kit (Invitrogen). Successfully 
transformed E.coli colonies were selected for by ampicillin resistance, and then a single colony 
was grown in 200 ml of liquid broth (l00 flg/ml amplicillin) overnight at 37°C. Plasmid DNA 
was isolated from the E.coli using the Qiagen Plasmid Midi Kit (Qiagen, Inc., Valencia, CA, 
USA). 
Sequencing of the Rat Nat3 Gene 
The Nat3 plasmid insert was completely sequenced USIng commercially available 
plasmid-specific primers 5' -taatacgactcactataggg-3' (T7 - forward), and 5' -tagaaggcacagtcgagg-
3' (BGH reverse), and newly designed gene-specific forward primers (5'-
tgcatactaccagaaatctccaa-3', 5' -tgccatcttccacttgacagaa-3', 5' -tcttctttactgggctctga-3'), and gene-
specific reverse primers (5' -cagtaaagaagatgattgacttgaa-3', 5' -gtcaattccagaggctcccacat-3', 5' -
gataagaatggtgcctactaaa-3'), to ensure complete coverage of both top and bottom strands of the 
sequence. Sequencing reactions were performed using BigDye Terminator v1.1 Cycle 
Sequencing Kit (Applied Biosystems, Foster City, CA, USA), and the sequencing analysis 
performed by an ABI 310 Genetic Analyzer (Applied Biosystems). Sequencing data were 
analyzed using SeqManII v.5.03 from DNASTAR Inc. (Madison, WI, USA). 
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Results & Discussion 
Rat Nat3 sequencing of both top and bottom strands was successfully accomplished for 
rat strains Fisher 344 (F344), Wi star Kyoto (WKY), and Sprague Dawley (SPRD) (Figure 10). 
No SNPs were found among all three strains sequenced. The sequence did, however, differ from 
the GenBank predicted sequence (XM_224762) by a single nucleotide. The predicted sequence 
from the BN strain contains a guanine at position 358, while the F344, WKY, and SPRD have an 
adenine at this position. The difference manifests itself in an amino acid coding change from 
valine (G at 358) to isoleucine (A at 358). Nucleotide sequence comparison of all known human, 
mouse, and rat N-acetyltransferase loci reveals that nucleotide position 358 is an adenine in all of 
them. Since the predicted Brown Norway Nat3 sequence resulted from a large-scale sequencing 
project instead of direct sequencing of the gene, it is unclear whether the difference between the 
predicted BN sequence and the F344, WKY, and SPRD sequences is indicative of a single 
nucleotide polymorphism or a sequencing error from the large-scale sequencing project. 
As is true with all known N-acetyltransferases, the Cys-His-Asp catalytic triad is present 
in rat Nat3, suggesting that it has true N-acetyltransferase catalytic activity. The three nucleotides 
determined to playa role in substrate selectivity (Goodfellow et aI., 2000) in Nat3 are unique 
among the human NATs and rat Nats, but identical to those found in the published mouse Nat3 
sequence (Figure 11). This suggests that Nat3 will have a unique substrate selectivity among rat 
Nats, but similar, if not identical, to mouse Nat3. Rat Nat3 nucleotide sequence is 76% identical 
to rat NatJ and 78% identical to rat Nat2; rat Nat3 amino acid sequence is 71 % identical to rat 
Natl and 72% identical to rat Nat2 (Figure 12). The highest amino acid and nucleotide sequence 
identity to rat Nat3 is with mouse Nat3, at 88.3% and 91.1 %, respectively. 
Analysis of chromosomal gene location using NCBI Map Viewer (Wheeler et aI., 2005) 
and BLAT from UCSC Genome Bioinformatics (Kent WJ, 2002) reveals that all three rat Nats 
are located within about 75 kb on rat chromosome 16. The order of the rat genes 5' to 3' is NatJ-
Nat2-Nat3, with about 10 kb between Natl and Nat2, and about 60 kb between Nat2 and Nat3. 
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1 ATG GAC ATT GAA GCG TAC TTT GAA AGA ATT GGT TAT CAG AAG TCC ACG AAC AAA CTG GAC 60 
M DIE A Y FER I G Y Q K S T N K L D 
61 TTG CAA ACA TTA ACT GAA ATC CTT CAG CAT CAG ATA CGG GCT ATC CCT TTT GAG AAC TTG 120 
L Q T L TEl L Q H Q I R A I P FEN L 
121 AAC ATC CAT TGT GGG AAA CCC ATG GAA CTG AGC TTA GAG GCC ACT TTT CAT CAC ATT GTG 180 
NIH C G K P MEL S LEA T F H H I V 
181 AAG AAG AAG CGG GGT GGG TGG TGT CTT CAA GTC AAT CAT CTT CTT TAC TGG GCT CTG ACC 240 
KKK R G G W C L Q V N H L L Y W A L T 
241 ATG ATA GGT TTT GAG GTC ACA ATG TTA GGA GGA TGT GTT TAT AGC CCT CCA ACC TGC AAA 300 
MIG F E V T M L G G C V Y S P P T C K 
301 TAT AGC AAC ACT ATG ATT CAC CTT CTA CTA CAG GTG ACC ATC AGT GGC AAA AAA TAT ATT 360 
Y S N T M I H L L L Q V TIS G K K Y I 
361 GTA GAT AGT GCA ~ CCA ~ TCC ~ CAG ATG TGG GAG CCT CTG GAA TTG ACA TCT GGA 420 
V D S A F P F S C Q M W E P L E L T S G 
421 AAG GAT CAG CCT CAG GTG CCT GCC ATC TTC CAC TTG ACA GAA GGG AAT GGA ATT TGG TAT 480 
K D Q P Q V P A I F H L T E G N G I W Y 
481 CTG GGA CAA ACT AAA AGA CAA GAA TTT GTT CCA AAC CAA GAA TTC ATT GAT TCT AAT TTT 540 
L G Q T K R Q E F V P N Q E F IDS N F 
541 CTT GAG AAG AAC AAA CAT AGA AAA ATC TAC TCT TTT ACT CTT GAA CCT CGA ACG ATT GAA 600 
L E K N K H R K I Y S F T L E P R T I E 
601 GAT TTC CAG AAC GTG AGT GCA TAC TAC CAG AAA TCT CCA ACA TCT GTG ATG ACA AAC ACA 660 
D F Q N V SAY Y Q K S P T S V M TNT 
661 TCA CTT TGC TCC CTG CAT ACC CAA GAA GGG GTC CAT GGT TTA GTA GGC ACC ATT CTT ATC 720 
S L C S L H T Q E G V H G L V G TIL I 
721 CAT AAG AAA TTC AAT TAT AAG GAC AAT GTA GAT CTT GTG GAG TTT AAG ACT CTG AAG GAA 780 
H K K F N Y K D N V D L V E F K T L K E 
781 GAA GAA ATA GAA GAA GTC CTG AAG CGC GTT TTT GGT ATT CGC TTG GAG ACA AAG CTT GTG 840 
EEl E E V L K R V F G I R LET K L V 
841 CCC AAA TGT GGT AAT TGG CTT TTT ACT ATT 870 
P K C G N W L F T I 
Figure 10. Rat Nat3 Nucleotide and Deduced Amino Acid Sequences 
The nucleotide sequence for rattus norvegicus N-acetyltransferase 3 (Nat3) was determined by 
automated DNA sequencing for strains Fisher 344, Wistar Kyoto, and Sprague Dawley. Deduced amino 
acid sequence is shown also. The locations of the catalytic triad (single underline), the sites influential in 
substrate specificity (double underline), and the one nucleotide/protein sequence discrepancy with 
reference XM_224762 at nucleotide 358 (bold) are marked as indicated. This sequence was published in 
GenBank for strains Sprague Dawley (A Y253757), Wistar Kyoto (A Y253758), and Fischer 344 
(A Y253759). 
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125 127 129 
A Human NAT 1 -DAGFGRSYQMW-
Rat Nat2 -DAGFGRSYQMW-
Mouse Nat2 -DAGFGRSYQMW-
B Human NAT 2 -DAGSGSSSQMW-
Rat Natl -DSAYGSSYQMW-
Mouse Natl -DSAYGGSYQMW-
C Rat Nat3 -DSAFPFSCQMW-
Mouse Nat3 -DSAFPFSCQLW-
Figure 11. Amino Acids 125, 127, 129 Influence N-acetyltransferase Substrate Selectivity 
Human NATl, rat Nat2 and mouse Nat2 share the same amino acids at sites 125, 127, and 129 
(phenylalanine-arginine-tyrosine) suggesting that these enzymes have very similar substrate selectivities. 
Human NAT2, rat Natl, and mouse Natl do not have identical amino acids at these sites; however, the 
amino acids are somewhat similar, suggesting that substrate selectivities may be similar. Rat and mouse 
Nat3 enzymes have identical amino acids at these sites (phenylalanine, phenylalanine, cysteine), suggesting 
that the substrate selectivities will be identical. 
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Figure 12. Human, Mouse, and Rat N-acetyltransferase Sequence Homologies 
Both nucleotide (bottom left half) and amino acid (top right half) sequence compari sons for 
human , mouse. and rat N-acetyltransferases were determined using EMBOSS pairwise alignment 
algorithms (Rice et aI., 2(00). The highest sequence identities, for both nucleotide and amino acid 
sequence comparisons, are between rat and mouse Nats. The lowest nucleotide sequence identitites. for 
both nucleotide and ami no acid sequence comparisons, are between Nat3 (rat and mouse) and the human 
NATs. 
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This order is the same for the mouse Nats on mouse chromosome 8, and also for human NAT! 
and NAT2 on human chromosome 8. Rat Nat3 sequences for strains SPRD, F344, and WKY 




CHARACTERIZATION OF RAT N-ACETYLTRANSFERASES NATl*13, NAT2*20, 
NAT2*21A, NAT2*21B, AND NAT3 BY CLONING AND RECOMBINANT EXPRESSION IN 
ESCHERICHIA COLI 
Introduction 
The usefulness of the rat as a model for N-acetyltransferase studies depends on a good 
correlation between rat and human N-acetyltransferases. Although the comparison of rat and 
human N-acetyltransferase nucleotide and protein sequences suggests that such a correlation 
exists, it must be confirmed experimentally. Rat Natl*13, Nat2*20, Nat2*21A, and Nat2*21B 
have been characterized already to some extent (Hein et aI., 1997; Doll and Hein, 1995). 
Previous studies determined that rat Natl and Nat2 have unique substrate selectivities 
that suggest rat Natl is similar to human NAT2, and rat Nat2 similar to human NATl, thereby 
suggesting a correlation between the rat Nat and human NAT enzymes. This inverse correlation 
is further supported by intrinsic stability data, which revealed that the trend for rats is Natl > 
Nat2, and the stability of human NATs has the trend NAT2 > NATl (Gray et aI., 1996). 
However, since rat Nat3 was recently discovered, the characterization of the rat Nats is 
incomplete. 
The slow acetylator rat Nat2*21A and Nat2*21B alleles have four SNPs each. Two of 
the SNPs in each slow allele are silent (G399 A and G522A in Nat2*21A; G399 A and C672T in 
Nat2*21B), while the other two cause y121I (G361 A) and y266I (G796A) amino acid changes in both 
slow alleles. Thus, while Nat2 *21 A and Nat2 *21 B differ in their nucleotide sequence at two 
positions (522 and 672), they code for identical proteins. Kinetic data suggest that Nat2*20 is 
rapid while Nat2 *21 A and Nat2 *21 B are slow, but also that there is a significant difference 
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between the expression of Nat2*21A and Nat2*21B (Doll and Hein, 1995). The validity of the 
last finding is in question, however, since a difference between Nat2*21A and Nat2*21B would 
require that the silent nucleotide differences between the two alleles somehow influence mRNA 
expression, mRNA stability, and/or translational efficiency due to alterations in mRNA structure. 
Further experiments are needed to delineate the mechanism of the rat Nat2 slow acetylator 
polymorphic alleles, and the difference between the two Nat2 slow alleles needs to be confirmed 
and characterized. 
To test the correlation between human NATs and rat Nats, understand the extent of their 
similarities, and thereby validate the rat as an in vivo model for this research and for future in vivo 
rat Nat research, the rat N-acetyltransferases were further characterized, as described in this 
chapter. For the first time all three rat Nat loci, including all three Nat2 enzymes, have been 
characterized in the same expression system, and at the same time. Rat N-acetyltransferase 
isozymes were characterized for catalytic activity, substrate selectivity, thermostability, and 
immunoreactive detection by various polyclonal antisera. In addition, experiments were 
performed to delineate the Nat2 slow acetylator mechanism and the relationship between the two 
slow Nat2 enzymes. Substrates tested include p-aminobenzoic acid (PABA), 4,4-methylenebis(2-
chloroaniline) (MOCA), N-(p-aminobenzoyl) glutamate (pABG), 4,4-methylenedianiline (MDA), 
4-aminobiphenyl (ABP), 2-aminofluorene (AF), and sulfamethazine (SMZ). PABA is a known 
human NAT1- and murine Nat2-selective substrate, while SMZ is a known human NAT2- and 
murine Natl-selective substrate (Estrada-Rodgers et ai., 1998; Grant et ai., 1991). The first and 
only suspected endogenous N-acetyltransferase substrate, pABG, is a folic acid catabolite and a 
human NAT 1- and murine Nat2-specific substrate (Estrada-Rodgers et ai., 1998; Minchin, 1995). 
4-Aminobiphenyl is a bladder carcinogen found in cigarette smoke (Schulte et ai., 1988; Vineis, 
1994); this carcinogen is acetylated by both human NATI and NAT2 and mouse Natl and Nat2, 
but with higher affinity for human NAT2 (Hein et aI., 1993) and for mouse Nat2 (Fretland et aI., 
1997b). 2-Aminofluorene is a carcinogen that has higher affinity for mouse Nat2 than Nat 1 
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(Fretland et ai., 1997b). MDA and MOCA are suspected human carcinogens (National 
Toxicology Program, 2002a/b) whose metabolism may be influenced by N-acetylation. 
Characterization of the rat Nats will lay a basic foundation for understanding rat N-
acetyltransferases, and facilitate evaluation of the probable importance of Nat3, since nothing is 
known about its activity and it has no human analog. Since mouse Nat3 has very low activity 
relative to mouse Nat I and Nat2 (Estrada-Rodgers et ai., 1998; Fretland et ai., 1997), the 
importance of rat Nat3, which is very similar to mouse Nat3 in nucleotide and amino acid 
sequence, is questionable. The information gained from these experiments is preliminary data to 
investigations using the rat as an in vivo model for N-acetyltransferase studies. 
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Methods 
Cloning Rat Nat2 and Nat3 
Rat Nat2 alleles were cloned from PCR products into a bacterial expression vector, 
whereas rat Nat3 was sub-cloned from the Nat3-pcDNA3.1 vector described in chapter IV into a 
bacterial expression vector. Rat Nat2*20, Nat2*2]A, and Nat2*2]B were amplified from the 
genomic DNA of rat strains F344, WKY, and NSD, respectively, using high fidelity Phusion 
polymerase (Finnzymes, Finland) and Nat2-specific PCR primers. The Nat2 forward primer has 
the sequence 5' -tctgaattcatggacattgaagcatactttgaaagaattggttat -3', with an EcoR] restriction site 
(underlined) designed into the 5' -end to facilitate cloning (Doll and Hein, 1995). The Nat2 
reverse primer was newly designed with the sequence 5' -atgcgactgcagctaaatggtaaaaaatcgatc-
accatgttt-3', with a Pst] restriction site (underlined) designed into the 5' -end to facilitate cloning. 
PCR products were purified using the QIAquick PCR Purification Kit (Qiagen). Purified Nat2 
PCR products and the PKK223-3 bacterial expression vector (Pharmacia-LKB Biotechnology, 
Piscataway, NJ) (GenBank M77749) were digested with EcoR] and Pst] restriction enzymes 
(New England Biolabs, Inc., Beverly, MA). The Nat3-pcDNA3.1 clone described in Chapter IV, 
and the PKK223-3 bacterial expression vector were digested with Xma] and Pst] restriction 
enzymes (New England Biolabs). Restriction digest products were separated by electrophoresis 
on a 0.6% agarose gel, then analyzed under long wavelength UV light (365 nm). For the 
digestion of PKK223-3, the band corresponding to the open vector was excised from the gel. For 
the digestion of the Nat2 PCR products and the Nat3-pcDNA3.1 vector, the appropriately sized 
band (-1000 kb) was excised from the gel. The restriction digested Nat2 and Nat3 products were 
then purified from the agarose gel using the Qiaex II Gel Extraction Kit (Qiagen). Ligation was 
then carried out with the cut plasmid, approximately 3 molar equivalents of the insert, and T4 
DNA-ligase at 37°C for 20 minutes. All clones were created in duplicate from duplicate initial 
PCR reactions, and water controls were used to ensure that there were no false positive Nat bands 
due to DNA contamination. 
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Transformation of Competent Escherichia coli 
NovaBlue competent cells (Novagen, Inc., Madison, WI) were transformed with ligation 
reaction products, then plated on LB-agar plates (containing 100 ~g/ml ampicillin for selection of 
E.coli containing the circular PKK223-3 vector, which contains the ampicillin resistance gene 
encoding ~-lactamase) and allowed to incubate overnight at 37°C. NovaBlue competent cells 
were used as an initial cloning host due to their high transformation efficiency. Colonies were 
tested for PKK223-3 plasmids containing the Nat insert by colony PCR using PKK223-3-specific 
forward (5' -ttatcagaccgcttctgcgt-3 ') and reverse (5' -gctgttgacaattaatcatcgg-3') primers designed 
by Dr. David Barker. Colony PCR was performed by heat denaturing transformed E.coli 
(corresponding samples were preserved by streaking on LB-agar plates and incubating overnight 
at 37°C), followed by PCR using Taq polymerase (Perkin Elmer Corp). PCR products were then 
subject to electrophoresis on a 1 % agarose gel. The presence of Nat-sized bands (-1000 kb) in 
the gel indicated the presence of the Nat insert. Water controls were used to ensure that there 
were no false positive Nat bands due to DNA contamination of the PCR reagents used for the 
PCR. One colony from each of the preserved successful bacterial colony streaks were used to 
inoculate 200 ml of LB (100 ~g/ml ampicillin), then incubated overnight at 37°C with shaking 
(225 rpm) Cells were centrifuged at 5000 x g, and plasmid DNA isolated using the Qiagen 
Plasmid Midi Kit (Qiagen), and plasmid DNA quantified using a Beckman DU-650 
spectrophotometer. 
To verify that the correct sequence was cloned into the plasmid, both strands of the Nat 
insert were sequenced using gene-specific sequencing primers. For the Nat3 clone, the primers 
described in Chapter IV were used, in addition to the PKK223-3-specific reverse primer 
described above. For Nat2 clones, four forward primers (5' -tctgaattcatggacattgaagcatactttgaaaga-
attggttat -3', 5' -tagaagtcatctttgatcaa-3', 5' -aagagaatggaacctggtac-3', cagcatccttgtttacaagt-3') and 
four reverse primers (5' -atgcgactgcagctaaatggtaaaaaatcgatcaccatgttt-3', 5' -tacctgagttttaggagtta-3', 
5' -agaagacagtttgctttcta-3', and 5' -acttagtacggtgacgacat-3') were used, in addition to the PKK223-
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3-specific reverse primer described above. Most of the Nat2 sequencing primers were designed 
by Mark Doll. Nat2 primers do not overlap with slow Nat2 allele polymorphic sites. 
Sequence-verified Nat-PKK223-3 plasmids were then transformed into competent JM 105 
E.coU. JM 105 E.coli glycerol stocks were plated on LB-agar (no drug). A single JM 105 colony 
was then used to inoculate 25 ml of LB (no drug), and grown to log phase by incubation at 37°C 
with shaking (225 rpm). Following centrifugation at 5,000 x g for 10 minutes, pellets were re-
suspended in 1110 volume cold TSB medium (10% PEG, 5% DMSO, 10 ruM MgCI2, 10 ruM 
MgS04, I X LB medium), and incubated on ice for 10 minutes. Cells were stored in 100 fll 
aliquots at -80°C until used for transformations. Competent JM I 05 E.coli were transformed with 
Nat-PKK223-3 plasmids and incubated overnight at 37°C on LB-agar (100 flg/ml) plates. The 
presence of the Nat insert was again verified by colony PCR. A negative control for enzyme 
assays was also created by transforming JMI05 competent E.coU with an empty PKK223-3 
plasmid. Natl *13-PKK223-3 clones were obtained from Mark Doll and transformed into 
competent JM I 05 E.coli as described above. 
Recombinant Expression in E.coli 
From frozen stock, samples were plated on LB-agar plates (100 flg/ml ampicillin), and 
incubated overnight at 37°e. Colony purification was performed by re-plating a single colony 
from the overnight incubation on an LB-agar plate (l00 flg/rnl ampicillin), and incubated 
overnight at 37°e. A single colony was chosen from the purification and used to inoculate 25 ml 
liquid broth (100 flg/ml ampicillin), which was then incubated overnight at 37°C with shaking 
(225 rpm). Subsequently, 200 rnl of LB (100 /-lg/ml ampicillin) was inoculated to an OD600 of 
0.2. This inoculate was then incubated with shaking (225 rpm) for approximately 3 hours at 3TC 
to an OD600 of 0.5 to 0.7. Immediately, the PKK223-3 tac promoter was induced by adding 
isopropyl-beta-D-thiogalactopyranoside (IPTG) to 100 ruM, then incubated for an additional 3 
hours. Following incubation, cells were immediately pelletted by centrifugation at 6,000 x g for 
10 minutes, then either processed immediately or stored overnight at -20°e. Bacterial cytosols 
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were prepared by sonication in 1120 volume (i.e. 10 ml for 200 ml culture) homogenization 
buffer (20 mM Na3P04, 1 mM EDTA, pH7.4, I mM DTT, protease inhibitor cocktail), followed 
by centrifugation at 15,000 x g. Cytosols were aliquoted into 1.5 ml tubes and stored at -80°C. 
Total protein concentration was determined by the Bradford method (Bio-Rad Laboratories, Inc., 
Hercules, CA) (Bradford, 1976). Cytosols were ali quoted and stored at -80°C. 
Enzymatic Activity Assays 
N-acetylation activity was measured usmg bacterial cytosolic preparations containing 
recombinantly expressed Natl 13, Nat2 20, Nat2 21A, Nat2 21B, Nat3, or the PKK223-3 
negative control (no insert). Cytosols were incubated with 1 mM acetyl-CoA and 100 llM or 300 
llM substrate for 10 minutes at 37°C. Enzymatic reactions were stopped upon addition of acetic 
acid to 0.1 M to precipitate the protein. Precipitated protein was removed by centrifugation at 
13,000 rpm for 10 minutes, and the remaining supernatant analyzed by high performance liquid 
chromatography (HPLC) using System Gold Software (Beckman-Coulter, Fullerton, CA, USA) 
for quantification of N-acetylated product. Tested compounds include the following known Nat 
substrates: p-aminobenzoic acid (PABA), 4,4-methylenebis(2-chloroaniline) (MOCA), N-(p-
aminobenzoyl) glutamate (pABG), 4,4-methylenedianiline (MDA), 4-aminobiphenyl (ABP), 2-
aminofluorene (AF), and sulfamethazine (SMZ). HPLC methods for each substrate were 
developed by Mark Doll. 
Enzyme activities were normalized to the time of the reaction (10 minutes) and the total 
protein concentration as determined by the Bradford method (Bio-Rad) resulting in units 
nmoles/min/mg. Initial enzyme activity measurements were performed using the above reaction 
conditions for serial dilutions (1: I, 1 :5, 1:25, 1: 125, 1 :625) of each recombinant lysate. For each 
lysate-substrate reaction combination, the dilution that resulted in less than 15% conversion of 
substrate to product was chosen to ensure that the enzyme's activity is not affected by limiting 
substrate availability. Thus, activities were measured at initial rate conditions and the data are 
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reported as initial velocities. 
N-acetylation activity was measured for each substrate in triplicate, in addition to a no-
acetyl-CoA control to ensure that the reactions are acetyl-CoA dependent. The negative control 
activity was subtracted from the sample activities. Initial velocities are reported in nmoles 
acetylated substrate per minute reaction time per mg total protein (nmoles/min/mg) with standard 
error of the means (SEM) calculations for each. 
Kinetic Parameters 
To calculate Km (IlM) and V max (nmoles/min/mg) kinetic properties, initial velocities were 
measured, as described above, at a minimum of six different substrate concentrations. The data 
were fitted to a non-linear regression curve using GraphPad Prism V2.01 software (GraphPad 
Software, Inc., San Diego, CA). V max is the maximal rate of product formation and Km is the 
substrate concentration at Y2 Vmax (Michaelis-Menton Constant). A much more informative 
parameter is the specificity constant, which is the rate of substrate capture, calculated as V maJKm 
(Fersht, 1998). In addition to Km and V max, the specificity constant was calculated. 
Thermostability Assays 
Recombinant Nat J, Nat2, and Nat3 lysates were diluted to 1 )1g/ml in homogenization 
buffer, then incubated at 50°C for 5, 10, 20, 40, 60, and 80 minutes. Incubated lysates were 
transferred to ice immediately following the allotted time and assayed for N-acetylation activity 
as described above. Activities in nmoles/min/mg were normalized to the activity prior to any 
inactivation by calculating the percent original activity remaining, with the highest activity at 
100%. Data were fitted to a first order decay curve using GraphPad Prism software, with which 
the half-life (T y, ) and heat deactivation constant (k) were calculated. 
Characterization of N-acetyltransferase Polycional Antisera for Rat Nat Detection 
The specificity of various N-acetyltransferase polycional antisera for rat Natl versus Nat2 
was characterized by SDS-PAGE and Western blotting using rat Nat recombinant lysates. These 
antisera were also used to study the mechanism of the rat Nat2 slow alleles. To develop rat Nat3 
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polyclonal antiserum, a Nat3-specific peptide was designed based on the same strategy used for 
the rat Nat1 and Nat2 polyclonal antisera production (Figure 13), then developed commercially 
through Invitrogen (Carlsbad, CA, USA). 
Recombinant lystaes were diluted with homogenization buffer to 2 f.Lg/ml, and then diluted 
to 1 f.Lglml by adding an equal volume of 2 X Laemmli Sample Buffer (Bio-Rad). Samples were 
then denatured by addition of ~-mercaptoethanol (to 5%) and immersed in boiling water for 5 
minutes. To load 20 Ilg of total protein, 20 III of I f.Lg/ml sample was loaded onto a preformed 
12% polyacrylamide gel (Cambrex, East Rutherford, NJ, USA). Samples were electrophoresed at 
125 V for 2.5 hours in pre-mixed 1 X Tris/Glycine/SDS electrophoresis buffer (Bio-Rad 
Laboratories, Inc.). Protein bands were then electrically transferred from the polyacrylamide gel 
to Hybond-ECL nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ, USA) at 100 
V for 1 hour using pre-mixed 1 X Tris/Glycine transfer buffer (Bio-Rad). The membrane was 
blocked overnight at 4°C using Blocker BLOTTO in TBS (Pierce Biotechnology, Inc. Rockford, 
IL). The membrane was then washed 3 times for 10 minutes each time with wash buffer (25 mM 
Tris, 0.15 M NaCI, pH 7.2) (Pierce). The membrane was blotted with blocking buffer, 0.05% 
Tween 20 and primary antisera (diluted 1 :2000) for 2 hours at room temperature. Following 
another wash cycle (3 x 10 minutes), the membrane was blotted with blocking buffer, 0.05% 
Tween 20, and goat anti-rabbit horseradish peroxidase-conjugated secondary antibody 
(Amersham) diluted 1:50,000 for 1 hour at room temperature. Following another wash cycle (3 x 
10 minutes), the membrane was incubated in working chemiluminescent solution for 5 minutes 
using an ECL detection kit (Amersham Biosciences) exposed to Kodak Bio-Max film. 
Six different N-acetyltransferase antisera, in addition to the newly developed Nat3 
antibody were tested using the above method. The negative control cytosols (lysates of E.coli 




Peptide Design for Rat Nat Antibodies 
Natl N-VLKTTFGI SLEKKFVPKHGELVFTI-C 
Nat2 N-VLKT I FGVSLERKLVPKHGDRFFTI-C 
Natl N-VLKTTFGI SLEKKFVPKHGELVFTI-C 
Nat3 N-VLKRVFGI RLETKLVPKCGNWLFTI-C 
Nat2 N-VLKTI FGVSLERKLVPKHGDRFFTI-C 
C Nat3 N-VLKRVFGIRLETKLVPKCGNWLFTI-C 
Figure 13. Peptide Design Strategy for Nat3-specific Polyclonal Antibody Development 
Rat Nat I and Rat Nat2 polyclonal antisera were produced previously using a peptide identical to the 
C-terminal rat Nat I and Nat2 amino acid sequence. Since these antibodies successfully recognize their 
targets, this strategy was mimicked in designing peptide for producing rat Nat3-specific polyclonal 
antiserum . The peptide used for production of a Nat3 ant ibody originated from the C-terminal end of the 
Nat3 amino acid sequence. (A) The Natl and Nat2 peptides (underlined) differ by only six of the 17 amino 
acids shared between the two. (B) The rat Nat I and Nat3 peptides differ by seven of the 16 amino acids 
shared between the two, and also differ by additional three N-terminal amino acids in the Nat3 peptide and 
one additional am ino acid on the N-terminal end of the Nat I peptide. (el The rat Nat2 and Nat3 peptides 
differ by eight of the 16 amino acids shared between the two, and also differ by an additional three N-
terminal amino acids in the Nat3 peptide. Since the differences between Nat3 and Nat I , and between Nat3 
and Nat2 are greater than the differences between Nat I and Nat2, the resulting Nat3 polyclonal antiserum 
should be as select ive as the Nall and Nat2 antisera since it provides a seemingly sufficient number of 
Nat3-specific epi topes. 
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yeast cytosols containing recombinantly expressed NATI and NAT2 were used as the positive 
controls. Quantitation of Nat bands was achieved by normalization to non-specific bands. 
Protein bands were analyzed by densitometry. 
Bacterial RNA Isolation 
Total bacterial RNA was isolated from 1M I 05 E.coli using the RNeasy Kit from Qiagen. 
To test for quality, RNA was separated by electrophoresis on a 1 % agarose gel and analyzed for 
distinct 23S and 16S bacterial ribosomal RNA bands. DNA was removed from the RNA samples 
using the Turbo DNase kit from Ambion (Austin, TX), then re-analyzed by electrophoresis to 
confirm disappearance of DNA contamination, as is evident by the high molecular weight DNA 
bands visible at the top of the agarose gel. During this electrophoresis step, RNA was also 
quantified by including RNA standards in known amounts (200 ng, 400 ng, 800 ng). The bands 
were quantitated by densitometry. The concentration of the samples was then calculated using a 
standard curve. RNA samples were stored at -80°C. 
Real-Time RT-PCR 
Bacterial RNA was reverse transcribed to cDNA using SuperScript III First-Strand 
Synthesis System for RT-PCR from Invitrogen (Carlsbad, CA). Control reverse transcription 
reactions were performed in the absence of reverse transcriptase as controls for DNA 
contamination. The reaction mixture contained newly designed rat Nat-specific TaqMan primers 
(forward, 5' -agatgtgggagcctctggaatt -3'; reverse, 5' -gcaggcacctgag -3') from Applied B iosystems 
(Foster City, CA), a VIC-labelled rat Nat2-specific fluorogenic MGB probe (5' -cttccctgatgttaattc-
3') from Applied Biosystems, bacterial cDNA and TaqMan Universal PCR Master Mix from 
Applied Biosystems, which contains AmpliTaq Gold polymerase. Real-time PCR was performed 
using an ABI Prism 7700 sequence detection system from Applied Biosystems. The reaction 
conditions used for real-time PCR were previously described (Doll and Hein, 2002). Total RNA 
concentration was used to normalize the real-time PCR data. 
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Results & Discussion 
Cloning, Transformation and Recombinant Expression 
The coding exon of rat N-acetyItransferases NatJ*J3, Nat2*20, Nat2*21A, Nat2*21B, 
and Nat3 were successfully cloned into bacterial expression vector PKK223-3 (Pharmacia), as 
verified by sequencing with primers that span the entire top and bottom strands of the Nat 
sequence as well as the 5'- and 3'- sequence-vector interfaces. Successful transformation of 
JM 1 05 E.coli with each clone was verified by the ampicillin resistance that PKK223-3 conferred 
to the successfully transformed bacteria, and subsequently by colony PCR with gene- and 
plasmid-specific primers and gel electrophoresis. Recombinant expression was successful as 
verified by measurement of N-acetyItransferase activity in Iysates and by immunoreactive 
detection using Nat-specific polyclonal antibodies. Bacterial expression vector PKK223-3 
without insert was used as a negative control beneficial for cloning, transformation, and 
recombinant expression verification. 
Enzymatic Activity Assays 
N-acetylation activity was measured using recombinantIy expressed Natl*13, Nat2*20, 
Nat2*21A, Nat2*21B, and Nat3. Initial velocities were measured as described above for 
substrates p-aminobenzoic acid (PABA), 4,4-methylenebis(2-chloroaniline) (MOCA), N-(p-
aminobenzoyl) glutamate (pABG), 4,4-methylenedianiline (MDA), 4-aminobiphenyl (ABP), 2-
aminofluorene (AF), sulfamethazine (SMZ) (Figures 14-17). 
Initial velocity measurements confirmed that rat Nat3 is a functional N-acetyItransferase 
enzyme with distinct substrate selectivity, but with relatively low activity. Nat3 catalyzed the N-
acetylation of ABP, AF, MDA, and MOCA at low levels relative to Natl and Nat2, with its 
highest activity toward MDA and lowest activity toward MOCA. Nat3-catalyzed N-acetylation 
products were not detected with substrates pABG, PABA, and SMZ. No Nat3 selective substrate 
could be identified from the substrates tested. 
Natl catalyzed the N-acetylation of every substrate tested, with the exception of pABG. 
60 
N-acetylation of p-aminobenzoic acid (PABA) 
A 
Nat1 Nat2 20 Nat2 21A Nat2 21B 
N-acetylation of sulfamethazine (SMZ) 
B 
Nat2 21A Nat2 21B 







Enzymatic activities were measured in triplicate. Error bars represent the standard error of the 
means. (A) PABA is selectively acetylated by rat Nat2 20 (very low activity for rat Natl not visible on 
graph) over Natl, and Nat3 acetylation of PABA was not detected. (B) SMZ slightly prefers acetylation 
via Nat!, although Nat2 activity is substantial. Nat3 acetylation of SMZ was not detected. A significant 
difference between the activities of two Nat2 slow enzymes was observed for both PABA (p < 0.0001) and 
SMZ (p < 0.0001). 
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N-acetylation of 4,4'-methylenedianiline (MDA) 
A 
Nat221A Nat2218 Nat3 
N-acetylation of 4,4'-methylenebis(2-chloroaniline) (MOCA) 
B 
Nat2 21A Nat2 218 Nat3 
Figure 15. Rat Nat N-acetylation of MDA and MOCA 
Enzymatic activities were measured in triplicate. Error bars represent the standard error of the 
means. (A) MDA is selectively acetylated by Nat2 20. Nat3 acetylation was detected, resembling the 
activity of a Nat2 slow acetylator enzymes. (B) MOCA is selectively acetylated by Nat!. Nat3 activity 
was detected for MOCA at levels similar to Nat2 slow acetylators. A significant difference between the 
activities of the two Nat2 slow enzymes was observed for both MDA (p < 0.0001) and MOCA (p < 
0.0001). 
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N-acetylation of 4-aminobiphenyl (ABP) 
A 
0-0-' ~ j) _ NH2 
Nat2 21A Nat221B Nat3 















Nat2 21A Nat2 21B Nat3 
Figure 16. Rat Nat N-acetylation of ABP and AF 
Enzymatic activities were measured in triplicate. Error bars represent the standard error of the 
means. (A) ABP is a selective substrate for Nat2 20, but with substantial activity also via Natl. Nat3 
acetylation of ABP was detected at a rate similar to the Nat2 slow enzymes. (B) AF is selectively 
acetylated by Nat2. Nat3 acetylation of AF was detected at a rate similar to the Nat2 slow alleles. A 
significant difference between activities of the two Nat2 slow enzymes was observed for both ABP (p < 
0.0001) and AF (p = 0.0007). 
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Enzymatic activities were measured in triplicate. Error bars represent the standard error of the 
means. The potentially endogenous Nat substrate pABG was selectively acetylated by Nat2 enzymes with 
no activity detected for Natl or Nat3. The ratio of Nat2 rapid to Nat2 slow activities is much smaller here 
than for the other substrates tested, for unknown reasons. A significant difference between the Nat2 slow 
acetylator enzymes was observed (p = 0.0001). 
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Natl demonstrated the highest catalytic activity toward MDA, though MOCA was most 
selectively N-acetylated by Nat!. According to the comparison of ammo acids residues 
influential on substrate selectivity (Figure II), it might be expected that rat Natl would mimic the 
substrate preference of human NAT2. The human NAT2 selective substrate SMZ (Grant et ai., 
1991) was acetylated at a higher rate by rat Nat I than Nat2, though not to the degree required for 
classification as a rat Natl selective substrate. MOCA appears to be a superior rat Natl selective 
substrate, both for its selectivity and relatively high catalytic activity, and should be used for in 
vivo studies of rat Natl enzymatic activity instead of SMZ. The apparent difference in SMZ 
substrate preference between human NAT2 and rat Natl may reflect the influence of other 
differences between the enzymes that also playa role in substrate selectivity. 
For all substrates tested, rat Nat2 20 was a rapid acetylator relative to Nat2 21A and Nat2 
2IB, which were slow acetylators. This relationship is consistent with previous findings 
regarding these rat Nat2 enzymes (Doll et ai., 1995; Doll and Hein, 1995). All three rat Nat2 
enzymes acetylated every substrate tested, though all three acetylated PABA at the highest rate; 
in fact, PABA was highly selective for rat Nat2 over Natl and Nat3. This relationship is 
consistent with the comparison in Figure II, since PABA is selective for human NATI over 
NAT2, confirming the suspected correlation between the substrate selectivities of rat Nat2 and 
human NAT 1. Of those substrates tested, PABA is the clearly the substrate of choice for studies 
of rat Nat2 activity in vivo. 
An apparent paradox is observed in the difference between the activities of slow 
acetylators Nat2 21A and Nat2 2IB. This difference has been observed with multiple different 
clones by different people and at different times (Hein et ai., 1997). The observed differences are 
significant (GraphPad Prism unpaired t-test) for all substrates tested; ABP (P < 0.0001), MDA (P 
< 0.0001), MOCA (P < 0.0001), PABA (P < 0.0001), pABG (P = 0.0001), SMZ (P < 0.0001), AF 
(P = 0.0007). Since these enzymes are identical in their primary amino acid sequence, the 
different activities suggest differences at the level of transcription and/or translation. Since the 
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differences between the two alleles at the nucleotide level are silent (GmA in Nat2*21A; C672T in 
Nat2*21B), one or both of these silent nucleotide polymorphisms may contribute to the activity 
difference between the al1eles. This activity difference could come by way of alternative codon 
usage and/or alterations in mRNA expression and/or structure. This issue will be addressed 
further in experiments to follow. 
Kinetic Parameters 
The Michaelis-Menten constant (KnJ, the maximum velocity (V max), and the specificity 
constant (V/K) were calculated by fitting the data to a non-linear regression curve using 
GraphPad Prism software for the acetylation of AF by Natl 13, Nat2 20, Nat2 21A, Nat2 21B, 
and Nat3 (Figure 18), and of ABP for Nat I 13, Nat2 20, and Nat3 (Figure 19). The data 
demonstrate substrate-dependent Nat catalytic activity. 
N-acetylation of AF is accomplished most efficiently at all substrate concentrations by 
Nat2 20, which has both the largest V max and the largest specificity constant. The other rat Nats 
have comparable V max values to one another, with Nat3 having the lowest of them all. The two 
slow Nat2 enzymes have the lowest specificity constant due to their relatively large Km values, 
although they have higher V max values than Nat3; Nat3 apparently acetylates AF better than the 
Nat2 slow alleles at lower concentrations, but the Nat2 slow enzymes are more efficient 
acetylators than Nat3 at relatively higher concentrations. 
Nat2 slow acetylator polymorphisms appear to both reduced V max and increased Km of the 
enzymes, resulting in a smaller selectivity constant. The reduced V max may indicate reduced 
protein, though that should be confirmed with a Western blot analysis. Here, the apparent 
difference in activity between the Nat2 slow enzymes (Figures 14-17) manifests itself as 
significant differences in V max. but not Km. Reduced V max suggests reduced protein for Nat2 21 A 
relative to Nat2 2IB. Reduced Nat2 21A protein should be confirmed by Western blot. 
ABP is N-acetylated most efficiently by Natl at relatively low concentrations and by 
Nat2 at relatively high concentrations. Although Nat 1 has smaller V max than Nat2, it has a higher 
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Figure 18. Kinetics of Rat Nat N-acetylation of 2-Aminofluorene (AF) 
Rat N-acetyltransferases acetylate 2-aminotluorene with varying kinetics. Initial velocities were 
measured in triplicate (error bars and "±" values following data indicate SEM) for various dilutions of 
substrate. The non-linear regression fit and the calculated kinetic constants for each enzyme are shown 
above. The original location of the inset magnified portion is surrounded with a dotted line. Nat2 20 
acetylates AF most efficiently, followed by Nat! and Nat3. Nat2 slow alleles have the lowest specificity 
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Figure 19. Kinetics of Rat Nat N-acetylation of 4-Aminobiphenyl (ABP) 
Initial velocities were measured in triplicate (error bars and "±" values following data indicate 
SEM) for various substrate dilutions. The non-linear regression fit and the calculated kinetic constants for 
the data are shown above. The original location of the inset magnified portion is surrounded with a dotted 
line. While Nat2 20 has the largest V max, Natl has the largest specificity constant for AF N-acetylation; at 
relatively low substrate concentrations, Natl is a more efficient acetylator of ABP than Nat2, whereas the 
opposite is true at higher ABP concentrations. Nat3 has relatively low V max and selectivity constant. 
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specificity constant. Nat2 has the largest V max, but also has a very large Km, resulting in a smaller 
specificity constant than Natl. Nat3 has the smallest specificity constant, but acetylates ABP at 
Nat I-saturating substrate concentrations. 
These kinetic characterizations of recombinant rat enzymes 10 an artificial bacterial 
system are useful for general comparisons of the enzymes' activity and stability, but are limited in 
application since they do not necessarily reflect the characteristics of the enzymes in vivo. 
Thermostability 
Structural stability of the rat Nat enzymes was tested as thermostability (Figure 20). Nat I 
is the most stable of all rat Nat isozymes, showing no decrease in its activity after 80 minutes 
incubation at 50DC. Rat Nat3 is less stable than Nat I , having lost most of its activity by 80 
minutes of incubation, but considerably more stable than any of the Nat2 alleles. Nat2 20 is very 
unstable, having lost most of its activity within 5 minutes of incubation. 
The Nat2 slow alleles have reduced thermostability relative to Nat2 20. In fact, the rates 
of inactivation are so high that their activity was completely eliminated before the first time point 
(5 minutes) was taken. Significance between the inactivation rates of the two slow alleles could 
not be tested due to the rapid drop off of the enzyme activity following incubation. This was not 
pursued further since the two slow alleles produce identical enzymes. 
These data are consistent with inactivation data reported previously for all rat Nats except 
Nat3, which was not known at the time (Gray et aI., 1996). Here, it was determined that stability 
from highest to lowest is Nat1 » Nat3 > Nat2 20 > Nat2 21A/21B. The general relationship 
between Nat1 and Nat2 thermostability (Natl»Nat2) shows an inverse correlation with human 
NATI and NAT2 enzymes, where human NAT2 is much more stable than human NATl. 
Reduced enzymatic stability is apparently part of the mechanism for slow Nat2 acetylator 
phenotype. 
Characterization of N-acetyltransferase Antisera for Rat Nat Detection 
A number of polyc1onal antibodies have been developed for detection of 
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Heat Inactivation of Rat N-acetyltransferases 
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0 10 20 30 40 50 60 70 80 
Time (minutes) 
Half-Life Inactivation Rate 
Tv, (min) k (hr -I) 
Natl > 120 < 1.0 
Nat220 1.41 29.6 ± 1.1 
Nat22lA < 1.0 > 200 
Nat221B < 1.0 > 200 
Nat3 12.0 3.47 ± 0.33 
Figure 20, Thermostability of Recombinant Rat N-acetyltransferases 
Recombinant rat N-acetyltransferases were heat inactivated by incubation in at 50°C for 0, 5, 10, 
20, 40, 60, 80 minutes, then assayed for N-acetylation of 2-aminofluorene. Resulting N-acetylation 
activities were normalized to the enzyme's original activity prior to incubation (time = 0). In the plot 
shown above is a non-linear fit for one phase exponential decay (GraphPad Prism), with 100% on the Y-
axis represents the activity prior to incubation. Rat Natl is highly stable, with no detectable decrease in 
activity during the entire incubation. Rat Nat3 is of intermediate stability. The rat Nat2 enzymes, however, 
are very unstable, with Nat2 20 losing most of its activity within the first five minutes of incubation, and 
Nat2 21A and Nat2 2IB losing their activity almost immediately upon incubation. 
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N-acetyltransferase enzymes by Western blot. These include human, murine, hamster, as well as 
rat polyclonal antisera. The Nat3-specific polyclonal antiserum recently obtained from Invitrogen 
was included in these analyses. Once characterized, successful antibodies will be utilized for 
detection of Nats in tissues, where the concentration of Nat enzymes may be relatively low. 
Since rat tissues contain complex mixtures of multiple rat Nat isozymes, it is important that the 
antisera are isozyme-specific. Recombinant Iysates containing rat Natl 13, Nat2 20, Nat2 21A, 
Nat2 21B, and Nat3 offer the benefit of high Nat expression. Individually expressed recombinant 
rat Nats in a high-expression system is ideal for characterization of these antibodies. For the first 
time, all seven polyclonal antisera were characterized for rat Nat 1 , Nat2, and Nat3 specificity by 
Western blot (Figure 21). 
The polyclonal antibodies raised against rat Natl were sufficiently specific for rat Natl 
versus Nat2, and likewise the polyclonal antibodies raised to rat Nat2 were sufficiently specific 
for rat Nat2 versus Nat 1. The newly designed and produced rat Nat3 antiserum did not detect any 
of the rat Nats under the conditions tested. Of the other antibodies tested, one did not detect any 
of the rat Nats (human NAT2), and the rest of them detected both enzymes (hamster Nat2, mouse 
Nat 1 , mouse Nat2) to varying degrees. Since these antibodies were tested with bacterial cytosols, 
their specificity with regard to non-specific bands in rat tissues is not known, and background 
bands in these bacteriallysates are not of practical importance to this study. 
The rat Nat3 antiserum titer as determined by the company that developed the antibody 
(Invitrogen) indicates that polyc\onal Nat3 antibodes are present in the antiserum in amounts 
comparable to the rat Nat! and Nat2 antibodies in their antisera, although there are no guarantees 
that the antiserum will work for Western blotting. More Western blotting conditions should be 
tested to further characterize the Invitrogen Nat3 antiserum. The dilution of antibody, 
concentration of tween 20, time and temperature of incubation, and time of film exposure should 
be optimized to attempt to detect recombinant Nat3 using this antiserum. 
Since the epitope for rat Nat2 polyclonal antiserum production is located at the C-
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Figure 21. Polyclonal Antisera Detection of Rat N-acetyltransferases by Western blot 
Recombinant Iysates containing rat Natl 13, Nat2 20, and Nat3 were analyzed by Western blot 
using the available polycJonal antisera. The negative control is from Iysates of recombinant E.coli 
expressing empty PKK223-3 vector. The rat Natl polycJonal antiserum selectively recognizes Natl over 
Nat2 and Nat3, with a very small band for Nat2 « 2% of the Natl band). The rat Nat2 antiserum 
specifically recognizes Nat2 over Nat I and Nat3. Unfortunately, the newly developed rat Nat3 antiserum 
was unsuccessful at recognizing any of the rat Nats under the conditions tested. Other antisera recognized 
either none of the rat Nats or both rat Nat I and Nat2 to varying degrees. Mouse and hamster antibodies 
were obtained from Edith Sim, University of Oxford, UK. 
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terminus of the protein (Figure 13), and since none of the slow Nat2 polymorphisms affect amino 
acids region (there are only two amino acid differences between the rapid allele and either of the 
slow alleles), it is reasonable to think that all three Nat2 enzymes will provide identical epitopes 
for antibody detection. Therefore, any differences observed by densitometric analysis between 
the amounts of the rapid Nat2 enzyme and the two slow Nat2 enzymes will reflect a real protein 
difference and not a difference in the number of epitopes provided by the rapid enzyme versus the 
slow enzymes. 
The Nat2 Slow Acetylator Mechanism 
The mechanism behind the Nat2 slow acetylator alleles is unknown, and thus more 
experiments are required. Kinetic measurements (Figure 18) and thermo stability measurements 
(Figure 20) suggest that Nat2 21A and Nat2 21B protein levels are reduced compared to Nat2 20 
protein. A Western blot of recombinantly expressed Nat2 enzymes using the rat Nat2-specific 
polyclonal antiserum clearly revealed that Nat2 slow acetylator alleles do in fact have 
dramatically reduced protein levels compared to Nat2 20 (Figure 22). Combining what is known 
about Nat2 slow acetylator kinetics, thermostability, and protein level, points to the conclusion 
that Nat2 21A and Nat2 2IB protein are reduced due to decreased thermo stability (Figure 20), 
and the catalytic capability of the enzyme is reduced due to increase Km (Figure 18), the 
combination of which results in slow acetylator status. 
In addition to the difference between rapid and slow rat Nat2 catalytic activities, 
significant catalytic activity differences were observed between the cytosols expressing the two 
slow Nat2 alleles (Figures 14-17). The difference is also suggested by Western blot (Figure 22), 
in which the Nat2 bands are normalized to non-specific bands; nonspecific bands should be 
present in equal amounts across all samples in the same expression system. However, another 
Western blot must be performed and normalized to a bacterial housekeeping gene, or some other 
normalizing factor, to ensure that the small difference between recombinantly expressed Nat2 
21A and Nat2 2IB protein is real and significant. 
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Immunoreactive Detection of 




Figure 22. Immunoreactive Detection of Recombinantly Expressed Rat Nat2 Enzymes 
Recombinant Iysates containing Nat2 20, Nat2 21A, and Nat2 21B were analyzed by SDS·PAGE 
and Western blot. NatZ bands and a set of nonspecific bands were quantitated by densitometric analysis. 
Nat2 bands were normalized to the nonspecific bands, which were used as a loading control. Nat2 slow 
alleles produce drastically less protein in this system than the Nat2 rapid alleles. An apparent significant 
difference exists between the expression of the Nat2 slow enzymes. These data need to be confirmed by a 
Western blot normalized to an internal control, or other normalizing standard. 
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Recombinant Nat2 mRNA Expression 
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Nat2*20 Nat2*21A Nat2*21B 
Figure 23. Real-time RT-PCR Analysis of Recombinantly Expressed Rat Nal2 mRNA 
Total bacterial RNA containing recombinant Nat mRNA was subjected to real-time RT-PCR. The 
same primers and Nat2-specific fluorogenic probe were used for detection of all three alleles. The 
differences observed among the three alleles are not reflective of activity or apparent protein differences. 
The total mRNA levels do not reflect the corresponding enzyme activities, indicating that differences in 
mRNA expression do not cause the slow acetylator phenotype. In addition, the differences between the 
two slow acetylator alleles in activity, and possibly also protein, are not reflected in these mRNA 
expression data, but rather the opposite trend is observed. While the apparent reduction in mRNA 
expression for the slow alleles is numerically significant, it is most likely an artifact of the real-time PCR 
method. 
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The influence of Nat2 slow allele polymorphisms on mRNA expression was tested by 
real-time RT-PCR (Figure 23). These data show that the affect of Nat2*21A and Nat2*21B 
polymorphisms on protein expression level cannot be explained by reduction in mRNA 
expression. They also show that the apparent difference between Nat2 2lA and Nat2 2IB protein 
expression is not due to transcriptional differences, since the opposite trend is suggested. The 
apparently significant difference between mRNA levels for the rapid allele and the two slow 
alleles could be related to differences in real-time PCR efficiency, since the G399 A polymorphism 
in Nat2*21A and Nat2*21B is within a region to which one of the PCR primers anneals, thereby 
reducing PCR effIciency for the slow alleles. 
Thus, if the protein expression differences can be verified by a Western blot analysis 
normalized to a bacterial internal standard, the mRNA data indicate that in this system the silent 
SNPs that characterize the Nat2 slow alleles influence translation of the Nat2 21A and Nat2 21B 
enzymes. Possible translational differences might be caused by differences in codon usage and 
availability in this system, or altered mRNA structure which could result in differences in 
translational efficiency. 
Codon usage in E.eoli was analyzed based on the two codons that differ between the two 
slow alleles (Table 1) (Fuhrmann et ai., 2004; Nakamura et aI., 2000). This analysis led to the 
conclusion that the opposite trend (Nat2 21A > Nat2 221 B expression) would be expected if 
codon usage differences significantly influenced the translational efficiencies of the Nat2 *21 A 
and Nat2*21B mRNAs. In addition, the codon usage is practically reversed in rattus norvegieus 
for one of the codon pairs, indicating that if there were an influence of codon usage on 
translational efficiencies in the recombinant system it would be reversed in vivo. 
Since codon usage is apparently not involved in modifying translational efficiencies, 
recombinant mRNA sequences (Figure 24) were analyzed for folding differences using the Mfold 
program (Figure 25) (Mathews et ai., 1999; Zuker, 2003). Although the polymorphisms that 
distinguish Nat2*21A (G522A) from Nat2*21B (C672T) are silent in the amino acid sequence ofthe 
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Amino Codon Fraction Fraction Rat Nat2 
Acid Sequence (E.mU) (Rat) Allele 
Ser TCC 0.15 0.23 2*21A, (2*20) 
Ser TCT 0.17 0.18 2*21B 
Glu GAA 0.67 0.39 2*21A 
Glu GAG 0.33 0.61 2*21B, (2*20) 
Table 1. Codon Usage Comparison for Nat2*20, Nat2*21A, and Nat2*2IB 
To analyze the possible influence of differences in codon usage on Nat2*21A and Nat2*21B 
enzyme activity and possibly protein expression, the usage of the relevant codons was compared for this 
system. To test the correlation of any codon usage differences in this E.coli system to an in vivo rat model, 
the fraction of these codons for rattus norvegicus was also compared. Since the fraction of the GAA codon 
in E.coli is twice the fraction of GAG, codon usage comparisons suggest that Nat2 *21A might be expressed 
more readily than Nat2*21B, which is the reverse of what is observed experimentally. Although the Serine 
codon trend is correct, the difference between them is small and not likely significant. The codon usage in 
rat seems to be the reverse of what is seen in E.coli, suggesting that any effect of codon usage in this 
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Figure 24. Constructed Sequence of Recombinant Nat2 mRNA from PKK223-3 
Promoter and terminator sequences from the PKK223-3 bacterial expression vector sequence 
(Genbank M77749) were added to the 5'-and 3'-regions (respectively) of the Nat genes for analysis of 
predicted mRNA structures (Figure 25). (A) PKK223-3 contains an E.eoli tac promoter of the sequence 
shown (Amann et aI., 1983; De Boer et aI., 1983). The tae promoter start site is underlined (solid), and 
the Xmal restriction site is underlined (dashed). (B) PKK223-3 contains an rmB T,T2 ribosomal 
terminator (Brosius et aI., 1978). These constructs were designed based on termination use of the T, 
terminator (double underline) (Orosz et aI., 1991). The Pstl restricion site used for cloning is underlined 
(dashed) and the suspected termination codon underlined (solid) (Lyakhov et aI., 1997). (C) Suspected 
mRNA sequence for recombinantly expressed Nat2*2lA, with PKK223-3 promoter and terminator 
sequences in lower case (bold). 
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Figure 25. Mfold Predicted mRNA Structures for Recombinant Nal2 Slow Alleles 
The RNA folding prediction software, Mfold, was used to predict the mRNA structures of 
recombinantly expressed rat Nat2*2JA and Nat2*21B. Differences between the predicted mRNA 
structures are circled, with the associated polymorphism indicated where appropriate. These two alleles 
differ only by these two nucleotide changes, which are silent in the amino acid sequence. While this 
structure prediction does not take into account the tertiary structural interactions within the mRNA species', 
it gives some clues about what might happen to the secondary structure. The influence of the 0 522 A 
polymorphism in Nat2 *21 A may be to reduce the complexity of the folding slightly, whereas the influence 
of the C672T polymorphism in Nat2 *21 B seems to relax some of the structural complexity in that region. 
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coded proteins, they may have some influence on mRNA folding (Shen et a\., 1999) and thereby 
influence mRNA stability (Capon et a!., 2004) or translational efficiency. The Mfold server 
predicts folding changes associated with the two polymorphisms that distinguish the aIleles. The 
G522A polymorphism in Nat2*21A may reduce the complexity of the folding slightly relative to 
the Nat2*21A structure. On the other hand, the C672T polymorphism in Nat2*21B seems to 
release many of the structural folds in that region, relative to Nat2*21B. A change to lower 
complexity in this region affected by the C672T polymorphism is consistent with an increased 
translational efficiency for this allele, since ribosomal unfolding of this section might require less 
energy and time during translation. This change may also be consistent with a slightly decreased 
mRNA stability for the Nat2*21B recombinant mRNA, as suggested with real-time RT-PCR 
analysis (Figure 23). This would require the Nat2*21 B silent mutations to be more influential 
(relative to Nat2*21A) on translational efficiency than on mRNA stability. Due to the complex 
nature of an mRNA molecule, these predicted mRNA structures amount to speculation, an 
educated guess, and verification would require further experiments; such experiments are beyond 
the scope of this study and will not be performed. 
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Conclusions 
Rat Natl*13, Nat2*20, Nat2*2IA, Nat2*2IB, and Nat3 genes encode functional Nat 
enzymes with characteristic substrate selectivities, catalytic activities, and thermostabilities in 
vitro. MOCA is the best Natl-specific substrate, and PABA is the best Nat2-specific substrate. 
Although Nat3 is a functional N-acetyltransferase, it has relatively low activity toward every 
substrate tested and no comparable human N-acetyltransferase gene. Future in vivo Nat 
expression studies using rats need not include rat Nat3, since it does not appear to significantly 
influence overall N-acetylation and is relatively unrelated to human NATs. However, Nat3 
mRNA expression should be measured to verify that low rat Nat3 activity is not compensated for 
by high Nat3 expression in vivo. 
A correlation exists between rat Natl and human NAT2, and between rat Nat2 and 
human NATI. Evidence for this correlation was found in sequence similarity (Figure II), 
substrate selectivity (Figures 14-17), and thermostability (Figure 20). These similarities indicate 
that the rat is a suitable model for in vivo N-acetyltransferase studies. 
Rat Nat antisera are sufficiently specific for rat Natl and Nat2 (Figure 21). The newly 
designed and developed rat Nat3 antiserum was unsuccessful at identifying any of the rat Nats at 
the conditions tested. 
The mechanism of the rat Nat2 slow acetylators, Nat2 21A and Nat2 21B, involves 
elevated Km, thus reduced specificity constant (Figure 18), and reduced protein (Figure 22) due to 
reduced enzyme stability (Figure 20). Due to the polymorphic nature of rat Nat2, rats may serve 
as useful in vivo rapid and slow acetylator models. 
Although the Nat2 slow alleles differ only by silent nucleotide polymorphisms, their 
enzymatic activities differ significantly (Figures 14-17) possibly due to significant differences in 
protein expression (Figure 22). The possible differences in protein expression are not due to 
differences in mRNA transcription or mRNA stability (Figure 23). Possible translational 
differences cannot be explained by codon usage (Table 1), but they may be explained by 
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differences in translation efficiency due to differences in mRNA folding (Figure 25). 
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Future Experiments 
Of the substrates tested, PABA, SMZ, MOCA, MDA, and pABG need to be tested for 
kinetic parameters Km and V max' Additional prospective substrates have been identified, 
including p-aminoacetanilide, 3-amino-4-methoxyacetanilide, 3-ethylaniline, 2-amino-5-
nitrophenol, 4-amino-2-nitrophenol, 2,6-dimethylaniline, o-toluidine, and 3,5-dimethylaniline. 
These wiIl also be assayed for N-acetylation. Metabolic activation assays will be performed on 
N-OH-PhIP and N-OH-ABP with the new HPLC method developed by Mark Doll. 
Instead of relying on previously published data regarding human NAT activity, a more 
direct comparison of human NATl and NAT2 versus rat Nat! and Nat2 may be necessary. 
Human NATs will be recombinantly expressed in the same bacterial system using expression 
plasmids designed previously in this lab by Mark Doll, and assayed with substrates PABA and 
MOCA, which are rat Nat2 and Nat! selective, respectively. This will allow direct comparison of 
rat Nats to human NATs expressed in the same system. 
Optimization of Western blotting conditions will be tested to determine whether the Nat3 
antiserum will be useful for Nat3 detection. In addition, the rat Nat antisera will be tested for 
their detection of rat Nat proteins in vivo. Western blot will also be performed on the rat Nat2 
recombinant lysates and normalized to an internal standard. Since protein expression of the two 




TISSUE-SPECIFIC EXPRESSION OF RAT N -ACETYLTRANSFERASES: 
DISSERTATION AIMS AND EXPERIMENTAL METHODS 
Introduction 
The goal of my dissertation project is to investigate the influence of genetic background 
and cigarette smoke exposure on rattus norvegicus N-acetyltransferase 1 (Natl) and 2 (Nat2) 
mRNA and protein expression in various tissues. These studies will utilize rats as in vivo models 
to characterize and predict a mechanism for human N-acetyltransferase tissue-specific expression 
and the influence of both genetics and environmental exposures on human N-acetyltransferase 
tissue-specific mRNA and protein expression. These objectives will be accomplished upon 
completion of the following three specific aims: (1) Characterize the catalytic activity, substrate 
specificity, and thermostability of Sprague Dawley rat N-acetyltransferase isozymes by 
recombinant expression in Escherichia coli; (2) Characterize Natl and Nat2 mRNA and protein 
expression in multiple tissues of different rapid acetylator rat strains; (3) Investigate the influence 
of cigarette smoke inhalation on Natl and Nat2 mRNA and protein expression in multiple tissues 
of different rapid acetylator rat strains. 
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Specific Aim I 
Introduction 
Specific Aim I will characterize the catalytic activity, substrate specificity, and 
thermo stability of Sprague Dawley rat N-acetyltransferase isozymes by recombinant expression 
in Escherichia coli. While much of this aim was accomplished as described in chapters four and 
five, further experiments were proposed for completion of the work. The methods described in 
this section were not presented in chapter four or five, but will be utilized in addition to the 
methods outlined in chapter four and five for completion of analyses related and unrelated to 
Specific Aim I. Since a formal introduction to Specific Aim I can be found in chapters four and 
five, an extensive introduction will not be repeated here. 
The purposes of Specific Aim I are as follows: (1) Verify similarities in biological function 
between rat and human N-acetyltransferases (suggested by high sequence identities) in an effort 
to validate the rat as a suitable in vivo model for this research; (2) Sequence and characterize the 
previously unidentified rat Nat3 and determine its relevance to this study. 
The hypotheses that drive this aim are as follows: (1) Rat Nats are comparable to human 
NATs with regards to catalytic activity, substrate specificity, and thermostability, and therefore 
may serve an analogous physiological role; (2) Rat Nat3 is a functional N-acetyltransferase 
enzyme, similar in function to Nat! and Nat2, nevertheless with distinct catalytic activity, 
substrate selectivity, and thermo stability. 
Methods 
Colorimetric Determination of Enzyme Activity. Since HPLC assays are generally 
developed only for commonly assayed substrates, a different assay will be utilized for the less 
common substrates p-aminoacetanilide, 3-amino-4-methoxyacetanilide, 3-ethylaniline, 2-amino-
5-nitrophenol, 4-amino-2-nitrophenol, 2,6-dimethylaniline, o-toluidine, and 3,5-dimethylaniline. 
Incubation of recombinant lysates with acetyl-CoA and substrate will be performed as described 
in chapter five. Following incubation, guanidine HCI and sodium phosphate (pH 6.8) will be 
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added, followed by dithionitrobenzene (DTNB), sodium phosphate (pH 6.8), and 
ethylenediaminetetraacetic acid (EDTA) and incubation at room temperature for 5 minutes. 
During these incubations, CoASH is produced by reaction of free CoA, a byproduct of the N-
acetylation reaction and indicator of substrate conversion to product, with thiol-containing 
DTNB, resulting in a yellow color that will be quantified using a Beckman DU-650 
spectrophotometer to measure the absorbance of these samples at 412 nm (De Angelis et aI., 
1998). Control reactions containing no substrate will be included for each sample and each 
dilution to control for the absorbance of the total protein present in the reactions. Dilution buffer 
(homogenization buffer) must contain no dithiothreitol (DTT) or ~-mercaptoethanol since they 
produce a yellow color that will interfere with absorbance readings. Nmoles of acetylated 
product is inferred by multiplying the absorbance at 412 nm by the CoASH molar absorption 
coefficient 0.0137 (Riddles et aI., 1983). Activities will be calculated as nmoles/min/mg, and 
kinetic parameters will be determined as described in chapter five. 
Metabolic Activation Assay. Metabolic activation assays measure the formation of 
DNA-adducts from activated O-acetylation products (Figure 2). These assays will use 
recombinant bacterial lysates containing Nat1 13, Nat2 20, Nat2 21A, Nat2 2IB, Nat3, or the 
PKK223-3 negative control (no insert). Various enzyme dilutions will be assayed initially to 
determine the dilution necessary to ensure that < 15% total substrate concentration is consumed 
during the reaction. Cytosols will be incubated with 0.5 mM acetyl-CoA, 0.37 mM 2-
deoxyguanosine (Sigma) and 300 /lM substrate for 10 minutes at 37°C. Reactions will be stopped 
by adding water saturated ethyl acetate to precipitate the protein. Precipitated protein will be 
removed by centrifugation at 13,000 rpm for 10 minutes. Fifty III of the upper phase (organic) 
will be transferred to an HPLC vial, without disrupting the interface, then the solvent evaporated 
to dryness in a speed-vac for about 15 mintues. After drying, the adducts will be resuspended in 
10% acetonitrile with vortexing and analyzed by high performance liquid chromatography 
86 
(HPLC) using System Gold Software (Beckman-Coulter, Fullerton, CA, USA) for quantification 
of N-acetylated product. Compounds to be tested include N-OH-PhIP and N-OH-ABP. Methods 
for this assay were developed by Mark Doll. Data will be analyzed as described for the N-
acetylation assays in chapter five. 
Western Blot. Western blots will be performed on recombinantly expressed rat Nat2 20, 
Nat2 21A, and Nat2 2IB in an attempt to confirm the small difference between the two slow 
acetylator alleles (Figure 22). This will require use of a loading control. A re-probing step will 
be added to the previously described Western blot protocol in chapter five,. Instead of 
normalizing to a bacterial housekeeping gene, a commercially available monoclonal antibody 
against bacterial ~-lactamase (Abeam Inc., Cambridge, MA, USA) will be utilized. This antibody 
was raised in mouse, whereas the Nat antibodies were raised in rabbit, thus the membrane can be 
re-probed without a rigorous stripping protocol. Since ~-lactamase is expressed by the PKK223-
3 expression vector, this antibody will provide a way to directly normalize the Nat bands to the 
level of PKK223-3 expression in each preparation. The resulting protein bands will be 
quantitated by densitometry and the Nat bands corrected relative to ~-lactamase as the standard. 
87 
Specific Aim II 
Introduction 
This aim will investigate the mechanism behind the tissue-specific expression of rat Nats, 
which will lay the groundwork for aim three. As described in chapter one, little is known about 
the in vivo mRNA and protein expression of rat Nat] and Nat2 in any tissue. Experiments are 
proposed to analyze Nat expression in multiple tissues from multiple inbred rat strains to 
characterize N-acetyltransferase expression and the influence of genetic variability (trans-acting) 
on Nat expression. Only one publication to date reports rat Nat] and Nat2 mRNA sequences 
(from pineal gland), and asserts that rat Nat] and Nat2 share a single promoter (Ebisawa et aI., 
1995). This is not the expected result of these proposed studies. In fact, Ebisawa's findings have 
not been duplicated by other laboratories, or for other tissues, and are inconsistent with more 
recent studies of human N-acetyltransferase expression (Husain et aI., 2004). If, however, 
Ebisawa's results are duplicated in other tissues, the regulation of rat Nats will still have 
relevance for understanding the regulation of NAT expression with regard to promoter-dependent 
mRNA splicing and tissue-specific expression. 
Following exposure by ingestion, inhalation, or through the skin, many factors influence 
the NATl and NAT2 mediated metabolism of arylamines including: (1) the combined NATl and 
NAT2 genotypes, which determine rapid and slow acetylator status for each isozyme; (2) tissue-
specific NAT expression, which determines the tissue distribution of NAT 1 and NAT2 isozymes; 
(3) the characteristic tissue distribution of each arylamine, which determines each tissue's level of 
exposure to arylamine carcinogens; (4) Cytochrome P450 and other oxidation enzymes in each 
tissue, which determines the fraction of activated arylamine carcinogen; (5) competitive 
metabolism by other polymorphic xenobiotic metabolizing enzymes such as glutathione S-
transferases (Meisel P, 2002). Combinations of these factors will no doubt influence DNA-
adduction and possibly mutagenesis. DNA-adduct levels are a convenient gauge for the 
metabolic conversion of aryl amine carcinogens to reactive species, and are directly relevant since 
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DNA-adducts could be predictive of tumor incidence (Otteneder and Lutz, 1999). Therefore, in 
vivo DNA-adduct formation following arylamine exposure in rats will be the criterion used to 
prioritize the tissues selected for Nat expression analyses. This aim will focus initially on rat Nat 
tissue-specific expression in lung, liver, pancreas, bladder, kidney, prostate (male only), 
mammary gland (female only), and colon (Cummings et ai., 1994; Fretland et ai., 1997; Fretland 
et aI., 2003; Kaderlik et aI., 1994). Although enzymes other than N-acetyltransferases are 
involved in activation of arylamines, the tissues listed above are among the most critical sites for 
arylamine-induced cancer risk. Since N-acetyltransferases catalyze the activation and 
deactivation of arylarnines, these tissues demand the highest priority for a study related to Nat-
mediated cancer risk. 
In addition to tissue-specific expressIOn, this study will investigate the influence of 
genetic variability (trans-genetic background) on Nat expressIOn. Since single nucleotide 
polymorphisms In the coding region, even polymorphisms that are silent in the amino acid 
sequence, could influence Nat expression and compromise our ability to draw meaningful 
conclusions from differences in the expression of different alleles (Capon et aI., 2004; Shen et al. 
1999), only rapid acetylator rat strains will be chosen, each possessing the same Natl*13, 
Nat2 *20, and Nat3 coding region sequences. A number of rat strains were screened by 
automated sequencing of the complete Natl, Nat2, and Nat3 coding regions. Since the inbred 
strains used in this aim will not vary in their Nat genotypes, any variations in Nat gene expression 
must be due to the influence of either cis- (outside the coding region) or trans-acting genetic 
factors on rat Nat expression. Further experiments could allow distinction between cis- and trans-
genetic influence. 
The specific purposes of this aim are as follows: (I) Quantify the expression of Nat 1, 
Nat2, and Nat3 mRNA and protein in various rat tissues; (2) Characterize the use of differential 
promoters and alternative splicing patterns in rat Natl and Nat2 mRNA expression, and observe 
any associations with rat Nat tissue-specific expression; (3) Investigate the influence of genetic 
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background on rat Nat expression by comparing Natl and Nat2 tissue-specific mRNA and protein 
expression in different inbred rat strains. 
The hypotheses that drive this aim are as follows: (I) Rat Nats are tissue-specifically 
expressed with characteristic rnRNA and protein expression patterns for each tissue; (2) Nat 
expression is tissue-specifically regulated through differential promoter usage and alternative 
splicing of non-coding exons; (3) Cis- and/or trans-acting genetic factors may modify the 
expression of rat N-acetyltransferases at the rnRNA and/or protein level. 
Methods 
Genotyping Rat Strains. Rat genomic DNA from various inbred strains was isolated 
from blood samples (performed by Dr. David Barker) or ear clippings (performed by Mark Doll) 
that were purchased from Charles Rivers Laboratories, Inc. (Wilmington, MA) and Harlan 
Bioproducts for Science (Indianapolis, IN, USA). Natl, Nat2, and Nat3 were amplified from the 
genomic DNA by duplicate PCR reactions using with high-fidelity Phusion polymerase 
(Finnzymes). The PCR primers used for amplification of Nat2 and Nat3 were described in 
chapters five and four, respectively. The PCR primers used to amplify rat Natl (Forward, 5'-
ctggaattcatggacatcgaagcatacttcgaaaggattggttac-3'; Reverse, 5' -agagcatgcatggagacccaatttaccctaaa-
tagt-3') were designed by Mark Doll. Duplicate PCR reactions were combined, then PCR 
products purified using the QIAquick PCR Purification Kit (Qiagen). Purified PCR products 
were then run on a 1% agarose gel to verify the presence of PCR product. Following verification, 
the purified PCR products were sequenced (top and bottom strands) by automated DNA 
sequencing using the BigDye Terminator v l.l Cycle Sequencing Kit (Applied Biosystems), and 
reaction products analyzed on an ABI 310 Genetic Analyzer (Applied Biosystems). Sequencing 
primers were described in chapters V and IV for Nat2 and Nat3, respectively. Nat] sequencing 
was carried out using the two primers mentioned above, plus five additional forward and reverse 
primers (Forward, 5' -tctgctgtactgggctctga-3', 5' -aagagaatggaacctggtac-3' , 5' -
gcctctgtgtttgtaagcac-3'; Reverse, 5' -agaagacagtttgctttcta-3', 5' -acctggtaaagtgacgatat -3') designed 
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by Mark Doll. 
Of all the rat strains sequenced, PVG, MW, WF, DA, LoulM, CDF, BN, and LEW, in 
addition to F344 and SPRD, possess the wildtype Nat allele at all three loci (Table 2). Strains 
ACI and COP contained a new polymorphic Nat3 allele that will be submitted to GenBank upon 
verification. The predominance of the original Nat3 sequence (A Y253757) among the rat strains 
supports its designation as the wild-type Nat3 allele. 
Rat Selection and Care. For the following analyses, male and female rats from six 
different rat strains will be sacrificed without any prior experimental treatment. To eliminate 
variability in conditions with which the rats are raised, all rats will be ordered from Harlan 
(Indianapolis, IN) to ensure that they are raised under the same conditions. Rats will be obtained 
at an approximate age of 5 weeks, acclimatized to the University animal facilities for at least 5 
days prior to sacrifice or exposure (see Specific Aim III). Rats will be housed in plastic cages 
with wire bar tops. Ground corn cob bedding (1/4" deep) is changed at least two times a week. 
Diet will consist of Purina Lab Chow #5001. Room temperature will be maintained between 72-
74°C and humidity between 40-70%, with light/dark cycles of 12 hours (lights on at 6 a.m. and 
off at 6 p.m.). 
All experiments will be replicated in four animals (per strain). The total number of 
animals required for completion of this aim is approximately 48 (6 strains X 4 replicates X 2 
sexes). Rats will be sacrificed by exsanguination, making it possible to clear the rat tissues of 
blood prior to harvest. According to the recommendations of the Panel on Euthenasia of the 
American Veterinary Medical Association, death by exsanguination is an acceptable form of 
euthanasia if the animal is anesthetized prior to the procedure (A VMA Panel on Euthenasia, 
2001). To minimize the stress involved in administering anesthesia to the rats, the head will be 
covered with a cloth or towel, providing a dark environment while also preventing the animal 
from biting (Rassmussen and Ritskes-Hoitinga, 1999). 
Exsanguination and Tissue Isolation. Rats will first be anesthetized by 1M injection of 
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Inbred Strain Nat1*13 Nat2*20 Nat3 (A Y353757) 
ACIt ./ ./ G619T 
PVG ./ ./ ./ 
MW ./ ./ ./ 
WF ./ ./ ./ 
PETH ./ ./ ? 
DA ./ ./ ./ 
LOU/M ./ ./ ./ 
CDF ./ ./ ./ 
BN ./ ./ ./ 
LEW ./ ./ ./ 
copt ./ ./ G619T 
(F344) ( ./) ( ./) ( ./) 
(SPRD) ( ./) ( ./) ( ./) 
(NSD) ( ./) (2*21B) ( ./) 
(WKY) ( ./) (2*21A) ( ./) 
Table 2. N-acetyltransferase Loci Sequenced for Various Inbred Rat Strains 
Rat Nat loci from various inbred rat strains were sequenced to determine their genotype. 
Previously sequenced rat Nat loci from four other strains are also shown (parentheses). Of the above 
inbred rat strains, 10 possess wild type Nat], Nat2, and Nat3 alleles (underlined) Two strains possess 
identical polymorphic Nat3 alleles (t). 
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approximately 1 ml/kg + 50 )11 ketamine HCL (800 mg)/xylazine HCl (120 mg) solution (Sigma) 
(Flecknell P, 1996). Rats will then be sacrificed and exsanguinated by cardiac puncture. Krebs-
Henseleit bicarbonate buffer (Krebs et aI., 1932) saturated with a mixture of 95% O2 and 5% CO2 
will be perfused into the aorta using a 16 gauge needle for 3 minutes at 30 ml/min. The 
ascending vena cava will be cut immediately following puncture to allow the blood to drain. 
Lung, liver, pancreas, bladder, kidney, prostate (male only), mammary gland (female only), and 
colon tissues will be harvested. Triplicate representative tissue sections will be isolated from 
each tissue, then flash frozen in liquid nitrogen. Tissues will be stored at -80DC until further 
processing, with the exception of pancreas tissue, which, due to its high levels of ribonucleases, 
will be processed for RNA extraction immediately. 
Initial experiments will be performed to compare tissues harvested without 
exsanguination versus tissues that have been exsanguinated to determine whether blood Nat 
expression contributes significantly to mRNA and protein quantification. Since the extent of 
blood perfusion varies among tissues, blood could contribute to Nat expression measurements in 
a disproportionate manner, resulting in an inaccurate measurement of tissue-specific expression. 
RNA Isolation. Frozen tissue sections will be thawed in RNA STAT-60 (Tel-Test Inc., 
Friendswood, TX, USA) and disrupted for 1 minute in a bead-beater homogenizer. RNA will 
then be isolated from the tissue homogenates according to RNA STAT-60 protocol. 
Contaminating DNA will be removed from RNA using Turbo DNAlree (Qiagen). RNA will be 
stored at -80DC. RNA will be analyzed for quality by electrophoresis on a 1 % agarose gel. RNA 
standards of known concentration will be run on the same gel as the samples, and will be used to 
create a standard curve for quantification of RNA concentration. 
Protein Determinations. Frozen tissue sections will be thawed In ice-cold 
homogenization buffer, then disrupted for 1 minute in a bead-beater homogenizer. Cell lysates 
will then be centrifuged at 100,000 x g for 1 hour, and cytosol aliquots stored at -80DC. Total 
protein concentration will be determined using the Bradford method (Bio-Rad). 
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Measurement of Relative mRNA Expression. Although it was determined that Nat3 
should not be included in expression studies due to its lack of relevance to human NATs and 
relatively small contribution to N-acetylation activity, Nat3 will be included in initial 
determinations of relative rat Nat mRNA expression in tissues. This will enable further 
characterization of the contribution of rat Nat3 to overall N-acetylation in rat tissues, and examine 
the possibility that high Nat3 mRNA expression compensates for the low activity of rat Nat3 
enzymes. 
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) will be used to 
synthesize cDNA from rat tissue total RNA. RT-PCR reactions without reverse transcriptase will 
be performed as controls for DNA contamination. Natl, Nat2, and Nat3 mRNA levels will be 
measured by locus-specific quantitative real-time RT -PCR, normalized to I8S ribosomal RNA 
(Applied Biosystems), using TaqMan Universal PCR Master Mix from Applied Biosystems and 
an ABI Prism 7700 sequence detection system (Applied Biosystems). A single set of primers 
were designed to amplify of all three Nat loci simultaneously, and gene-specific fluorescent 
probes for detection of relative levels of Nat l, Nat2, and Nat3 in the same sample (Figure 26). 
PCR standards will be used to correct for differences among the three locus-specific 
MGB probes in sequence recognition and cleavage properties. Primers that flank the real-time 
PCR target region (Figure 27) were designed in order to amplify this region for creation of PCR 
standards. With these primers, PCR amplification will be carried out using high fidelity Phusion 
polymerase (Finnzymes), and PCR products then purified using the QIAquick PCR Purification 
Kit (Qiagen). PCR products will be quantified, then dilutions made and analyzed by RT-PCR to 
create a standard curve for quantification of Nat mRNA. 
The relationship 2-LlCT will be used to convert CT values from inverse logarithmic to linear 
scale, where ~CT is the I8S ribosomal RNA CT subtracted from the Nat-specific CT from the 
same sample. Control samples lacking reverse transcriptase and water controls (no cDNA) to test 
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Rat Nat Locus Real-Time RT-PCR Primer and Probe Design 
r-····1 
5' ----1i-:;4;:::i=====--:;4;=====~. 3' 
j Probe Rev Primer 
Fwd Primer : III 
3' ~4~----~! -+--------------1.. ....... .1 5' 
388 449 
Natl ccAG ATGTGGGAGC CTCTGG~AA~TT~~~~g~g~§~a~a~g~g.ATCAGC CTCAGGTGCCTGCcatctt 
Nat2 ccAG ATGTGGGAGC ~~~~~~~g~g§~a~a~g~g~ATCAGC CTCAGGTGCCTGCcatctt 
Nat3 ccAG ATGTGGGAGC CTCTGGAATT§ac tc~~aaggATCAGC CTCAGGTGCCTGCcatctt 
Nat Forward Primer Nat Reverse Primer 
S' - AGATGTGGGAGCCTCTGGAATT - 3' S ' -GCAGGCACCTGAGGCTGAT-3 ' 
Nan-Specific Probe <FAMl 
S '-CTTCCCTGAGGTTAATT-3' 
NaU-Specific Probe (VIC! 
S' - CTTCCCTGATGTTAATTC-3' 
Nat3-Specific Probe (TETl 
S'-CTTTCCAGATGTCAATTC-3' 
Figure 26_ Taqma n Primer and MGB Probe Design for RT-PCR Rat Nat Locus Discrimination 
Nucleotide sequence comparison of rat Natl , Nat2, and Nat3 reveals regions of nucleotide identity 
among the three loci surrounding a small region containing differences among the loci (highlighted). Non-
specific Nat real-time PCR primers were designed based on the identical regions (capitalized). Locus-
specific MGB f1uorogenic probes were designed to distinguish the three Nat loci based on the nucleotide 
differences (underlined). Since the sequence recognized by the probes overlaps with the forward primer 
(dashed box), the probes were designed to recognize the opposite strand without overlapping the reverse 
pn mer. 
95 
for DNA contamination will be included. 
Rat Nat mRNA Transcripts. The 5' RLM-RACE kit (RNA Ligase Mediated Rapid 
Amplification of cDNA Ends) from Ambion will be used to characterize Natl and Nat2 mRNA 
species in tissues of F344 strain inbred rats. This is a superior method for determining the 
complete 5' mRNA sequence because only mature. capped mRNA are amplified. Identification 
of the 3' poly-adenylation site(s} will be determined using Ambion's 3' RACE kit, which 
amplifies only mature, poly-adenylated mRNA. RACE products will be amplified by dual rounds 
of PCR using locus-specific nested PCR primers (Figure 27) and RACE adapter-specific primers. 
PCR products will be cloned using a pcDNA3.11V5-His Tapa TA Cloning kit (Invitrogen). 
Clones will be used to transfect TOPIO E.co/i (Invitrogen). Plasmids will then be amplified by 
growth in TOPIO E.co/i, followed by plasmid isolation using the Qiagen Plasmid Midi Kit. 
Plasmid inserts will be sequenced using plasmid-specific T7 (Forward) and BOH (Reverse) 
primers. If transcript length exceeds the range of these primers, new primers will be designed 
based on the known transcript sequence. Sequencing data will be analyzed for transcription start 
site and mRNA splicing patterns. Transcript sequences will be submitted for publication in 
OenBank. 
Due to the cost of RACE analysis and the large numoer of samples to be analyzed, rat 
strain F344 RACE results will be utilized to design Northern blot and RT-PCR analyses. 
Heterogeneity in Nat mRNA transcript profiles among different strains will be determined by 
comparison of the Nat transcripts by Northern blot. A high degree of variability in Nat transcript 
sizes among rat strains will justify performing RACE experiments on strains other than F344. If 
Northern blot analyses do not indicate such variability among strains, quantitative real-time RT-
PCR experiments can be designed using the F344 RACE data for quantification of the specific 
transcripts detected. 
Northern Blot. Total RNA (15-20 ~g) will be separated on an agarose gel made from 
NorthernMax lOX denaturing gel buffer (Ambion, Inc.) and run using NorthernMax running 
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C E F -- : j ~ ~ -.-== .-== 
A B 0 
Rat Natl 
ATGGACATCG AAGCATACTT CGAAAGGATT GGTTAs:AAGA ACTCA,aTGAA .!AA.GI.TGGAC TTGG~ACAT TAACTGAAQT - -
TCTTCAACAC CAGATQCG~G Cagttccttt tgagaatctt agtatgcact GT~~GAAGC CATG~TCTG QGCTTAGAGG 
CCACTTTTGA £CACAT~GT~ AGG~GC GGGGTGGGTG GTGTCTCCAG GTTAATCATC TGCTGTACTG GGCTCTGACC 
AAAATGGGTT TT~CCAC AATGTTGGGA GGATATGTTT A9-T~CTCC AGTCMCAAA TATAGCAGTG AAATGGTCCA 
CCT~TGGAAG CTCCT"tcAG:;A'l'G'l'QGGAG(l 
CGTTTGACAG AAGAGAATGG MCCTGGTAC 
CTCGGACCTC CTTGAAAAGA QCAAATATCG 
AAAAATCTAT TCCTTTACTC TTGAGCCCCG CACTATTGAG GATTTTGAAT ATGTAAATAC CTACCTTCAG ACATCGCCAG 
CfTCTGTGTT TmA,AGCACA TCQTT.£TGTT CCTTgcagac c tcagaaggg gt t~CTGTT T~TTGG!TC CACCCTTACA 
AQTAGGAGAT TCAGTTATAA GGACAATGTA GATCTQGTTG AGTTTAAGAG TCTGACTGAG GAAGAAATAG AAGATGTACT 
GAAAACCACA TTTGGCATTT CTTTGGAGAA AAAG,!TTGTG 
A 5'-TGGCCAAGTCCAACTTATTCACT- 3' 
B 5'-agtgcacactaagattctc aaa aggaact -3' 
C 5' - CGAGCagttccttttgagaatcttag- 3' 
Rat Nat2 
ATGGACATTG AAGCATACTT TGAAAGAATT GGTTATCAGA 
TCTTCAACAC CAGATACGGG CTATTCC~TT TG~CTTG 
.!:,ca..t.Qtttga tca~tt9t9 aGGAAGAAGC G,!GGTGG~TG 
AAAATGGGCT TTGAAGCCAC AATGTTGGGA GGGTATGTCT 
CCCAAACATG G,£GA!C!CGT TTTTACTATT TAG 
D 5' - cAAGGAACAGAACGATGTGCTTAC- 3' 
E 5' - g cagacctcagaaggggtttg-3' 





CAAACTGGAC TTGG~T TAACTGAAAT 
G~GGGGAATC CATGGAGCTG AAtttaga~g 
GTTAATCATC TGCTGTACTG GGCTCTGACC 
AGCCAA,!AAQ TACAGCAGTG GCATGATTCA 
~~~~~~~~~~~~~~~~~~~~~~~~ QGTTTGG"CG TTCCT~A~  ~ C ACA AAGAGAATGG AACCTGGTAC
TTGGACCAAA TCAGAAGAGA GCAGTATGTT CCAAACCAAG AGTTTGTTAA CTCAGACCTC CTTGAAAAGA ACAAATATCG 
AAAAATCTAT TCCTTTACTC TTGAGCCCCG CACTATTGAG GATTTTGAGT .£C!TTAATAC CTA!CTTCAG ACATCGCCAG 
CATCcrTGTT TACAAG!A¥- TCATTTTGTT CCTTGCAGAC CCTAGAAGGG GTTCACTGTT TQGTTGGCTC CACCCTCACT 
TATAGGAGAT TCAGTTATAA GGACAATATA GATCTTGTAG AGTTTAAGAG TCTGACTGAG GAAGAAATAG AAGACGTACT 
GAAAAC!ATA TTTGGGgttt cttt!;gagag aaagcttgtg cc!:.AAACATG GTGATCGATT TTTTACfATT TAG 
A 5 ' - TCTGGTGTTGAAGAATTTCAGTTAATTC- 3' D 5' -GCGATGTCTGAAGATAGGTATTAATGG- 3' 
B 5'-tcacaacttgatcaaagatgacttc taaat- 3 ' 
C 5'-CCATGGAGCTGAatttagaagtca t -3' 
Rat Nat3 
E 5' - GTACTGAAAACTATATTTGGGGtttcttta -3 ' 
P 5' - tttctttagagagaaagcttgtgcct - 3' 
ATGGACATTG AAG02TACTT TGAAAGAATT GGTTATCAGA AGTCCACGAA CAAACTGGAC TTG~CAT TAACTGAAAT 
ccttcagcat cagatacggg cTATCCCTTT TGAGAACTTG AACATCCATT GT~CC CATGGAACTG AGCTTAGAGG 
CCACTTTT~A TCACATTGTG ~GAAGAAGC GGGGTGGGTG GTGTCT,!C~ GTfAATCATC T,!CT!TACTG GGCTCTGACC 
A~AT~GGTT TTGAQGICAC AATGTT~GGA GGATQTGTTT ATAGCfCTCC A!CClGCAAA 
CCTTCTAfTA CAGGTGACCA TCAGTGGCAA AAAATATATT GTAGATAGTG CATT~AT,! 
CA: 00Il C C~TTGACAG 
~TGG~CAAA ~GA£A 8Q~T,!TGTT CCAAACCAAG ~TT~TTQA !TCT~TTTI 
AAAAATCTAf TCITTTACTC TTGAACCTCG ~CQATTG~ GATTT~AG~ ACGTGA§TQC ~TAC~CAG ~TC,!CC~ 
CATCTGT~T §AC~CACA TCACTTTGCT CCfTGCA!AC CCAAGAAGGG GT£C~TT TAGT~GG~C CAIICTTA! C 
CAT~~T TC~TTATAA GGACAATGTA GATCTTGTGG AGTTTAAGAf TCTGAAGG~ GAAGAAATAG AAGAAGTCCT 
GAA~CQT! TTTGGTATT~ ~TTGGAGAC AAAGCTTGTG CCCAAA~ GT~T!GGCT TTTTACTATT TAG 
(A 5'- tgctgaaggATTTCAGTTAATGTTTG- 3') 
(B 5' - gccc9tatctga~gct9aa9g- 3'j 
C 5' - CTCCAACCTGCAAATATAGCAACA- 3' 
D 5'-GTCTTTTAGTTTGTCCCAGATACCAAA-3' 
(E 5' -GAAGAAATAGAAGAAGTCCTGAAGCG-3'j 
(F 5' -GACAAAGCTTGTGCCCAAATG -3'j 
Locus-specific Base (S ingle) r,psus _Spe c ific BaeA6 (Multiple ) • 
Figure 27. Primer Design for Real-Time PCR Controls and PCR of RACE Products 
Nested Primers A and B were designed for 5 ' RLM-RACE product PCR; E and F were designed for 
3' RACE product PCR. Primers C and D, which encompass the real-time PCR target region (highlighted) 
(Figure 26) will be used for creation of real-time PCR standards. Primer location is indicated by bold 
and/or lower case text. 
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buffer (Ambion, Inc.). RNA will then be transferred to BrightStar-Plus Positively Charged Nylon 
Membranes (Ambion, Inc.) using NorthernMax One-Hour Transfer Buffer (Ambion, Inc.). 
Probes will be labeled, hybridized, and detected using the North2South Direct Labeling and 
Detection Kit (Pierce, Inc.). Nat RNA bands will be analyzed by densitometric analysis. Probes 
specific to the Nat coding exon of the two Nat loci will be used identify locus-specific transcripts. 
Quantification of Relative Protein Expression. Western blotting will be used to 
quantify the relative expression of Nat] and Nat2 protein in rat tissue cytosols. SDS-PAGE and 
Western blotting will be carried out as proposed under Specific Aim I, normalizing to a-tubulin 
as the internal control. For quantification, a correction factor will be calculated using purified 
Nat proteins of known concentrations. This correction factor will be applied to the band intensity 
for each isozyme to correct for differences in antibody concentration. Nat enzymes will be 
recombinantly purified using the IMPACT -CN Protein Fusion and Purification System (New 
England Biolabs, Inc.). In this system, enzymes are recombinantly expressed as fusion proteins 
with a self-cleaving intein and chitin binding affinity tag. The affinity tag permits purification 
using a chitin column, and the intein self-cleaves under reducing conditions (dithiothreitol) 
leaving only the native enzyme. Enzyme concentration will be measured using the Bradford 
method (Bio-Rad). The ECF detection kit (Amersham Biosciences, Inc.), in combination with a 
Molecular Dynamics Storm 860 phosphorimager (Amersham Biosciences, Inc.) enables 
quantitative measure protein bands directly from the membrane. Dilutions of purified Nat 
enzyme will be used to create a standard curve for quantification of protein from Nat band 
intensities. These standards will be included on each gel. 
Enzymatic Activity Assays. N-acetylation assays will be performed as described in 
chapter five, but tissue cytosols will be used in the place of recombinant bacterial lysates. 
Isozyme-selective substrates will be used to distinguish Nat] enzyme activity from Nat2 activity. 
These substrates will be the most selective for each isozyme, as determined using the substrate-
selectivity data from Specific Aim I. 
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Metabolic activation assays will be performed as described above under Specific Aim I 
with substrates N-OH-PhIP and N-OH-ABP, but tissue cytosols will be used in the place of 
recombinant bacterial lysates. The negative control will be a boiled tissue cytosol sample at the 
same concentration as the normal tissue cytosols, since the activated arylamines will react with 
protein and DNA. 
Distinction of Cis- and Trans-Genetic Influence. Although not a primary goal, it may 
be possible to distinguish between cis- or trans-acting genetic factors with an FI hybrid cross 
between two strains that differ in their Nat expression. We can quantitatively measure the total 
Nat mRNA for the locus of interest (locus "NatX") in the FI hybrid and compare with the 
expression in both of the parent strains. If the total NatX mRNA in the FI hybrid is identical to 
the total NatX mRNA in one of the parent strains, we can conclude that functionally important 
dominant trans-acting genetic factors are influencing NatX expression in that parent strain. If, 
however, the hybrid NatX mRNA level is intermediate between the two parent strains, we cannot 
distinguish between cis-acting and trans-acting genetic factors. 
Statistical Analyses. Standard error of the means (SEM) will be calculated for 
triplicate measurements of Nat mRNA expression, protein expression, and enzyme activity in 
each tissue tested. Likewise, SEM will be calculated to test the variability of mRNA expression, 
protein expression, and enzyme activity mean values for each tissue among four replicate 
animals. Tukey parametric one-way analysis of variance will be performed to test the influence 
of strain differences on expression in each tissue. This same analysis (Tukey) will be utilized to 
analyze the differences among different tissues within each strain for significance of tissue-
specific differences. This test compares every possible pair of measurements within the group for 
significant differences, and eliminates errors associated with performing many individual t-tests. 
Statistical significance will be determined at values of p < 0.05. 
Potential Additional Analyses and Controls. If significant differences are found in the 
expression of Nat loci among different strains, microarray analysis of tissue RNA from different 
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rat strains could provide clues regarding biomolecular pathways that may be involved in Nat 
regulation. Since different strains typically model a specific pathology or trait, possible 
differences in the regulation of Nat expression in these strains relative to other important gene 
families could provide important information about the endogenous physiological function of Nat 
and its connections to biomolecular pathways (Staudt and Brown, 2000; Le Roch et aI., 2003). 
The Brown Cancer Center Microarray Facility provides equipment and expertise necessary for 
successful rnicroarray experiments. GeneChip Rat Genome 230 2.0 Array (Affymetrix, Inc) 
provides comprehensive coverage of the rat genome, analyzing over 30,000 rat transcripts and 
variants, and therefore is very useful for analysis of genetic variability and for comparisons of Nat 
expression with the expression of other biomolecular pathways. 
Potential Setbacks and Alternate Methods. In the event of failure to purify the rat Nat 
isozymes using the IMPACT-CN system (New England Biolabs), two alternative methods are 
available. Recombinant expression of tagged proteins can produce large amounts of protein that 
are easily purified. Although purification of tagged proteins is relatively simple experimentally, 
it is unclear whether the tag will alter native enzyme activity. Enzyme assays can be used to 
determine the effect of a tag on enzymatic activity by comparing tagged enzyme Western blot 
intensities and enzyme activities to recombinantly expressed Western blot intensities and enzyme 
activities. If tagging the enzymes alters their activity, Western blot analyses of recombinant 
expressions correlated to recombinant enzyme activity can be used to develop correction factors. 
Correlation of quantified Nat protein to enzyme activity will enable quantification of active Natl 
and Nat2 enzyme from enzyme activity assays with tissue cytosols, thereby also allowing 
comparison of Natl and Nat2 active protein levels. Also, since detection of the purified enzyme 
by Western blot does not require catalytically active enzyme, the tag should pose no threat to its 
effectiveness as a standard for Western blot analyses. Tags should not interfere with the peptide 
epitope used for production of the antibody. Alternatively, a synthetic peptide identical to the 
peptide against which the anisera were produced can be used as an arbitrary standard for 
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quantitation of the protein amount and the enzyme activity. Inability to quantify Nat protein and 
inability to compare active Nat I and Nat2 enzyme are the major disadvantage of this approach. 
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Specific Aim III 
Introduction 
This study will characterize the influence of one possible environmental influence, 
cigarette smoke inhalation, on rat Nat mRNA and protein expression in multiple tissues. Humans 
are regularly exposed to cigarette smoke either actively or passively. If the components of 
cigarette smoke influence NAT expression, the high prevalence of this exposure could be one 
possible cause for variable NAT phenotypes in a population. Cigarette smoke inhalation 
influences the expression of a number of genes, including the induction of oxidative stress-
responsive, Phase II-responsive, and Phase I-related genes (Gebel et aI., 2004; Roos et aI., 2003). 
Since cigarette smoke contains many different compounds, this aim will not attempt to delineate 
which chemicals influence Nat expression. The aim is simply to determine whether cigarette 
smoke, as a single environmental exposure, influences Nat expression. 
Cigarette smoke could be expected to influence Nat tissue-specific expression by several 
mechanisms. Cigarette smoke could specifically influence lung Nat expression since the smoke 
is introduced into the body directly through the lungs. Smoke components could tissue-
specifically influence the expression of trans-acting genes that in tum influence Nat expression. 
Cigarette smoke exposure could influence Nat expression in a strain-dependent manner due to 
genetic background differences. Any influence on Nat expression will most likely be very 
complex, but it will not be the goal of this study to delineate the mechanism(s) of cigarette smoke 
influence on Nat expression. 
The specific purpose of this aim is to test whether cigarette smoke exposure influences rat 
Nat] and/or Nat2 mRNA expression, protein expression, and/or enzyme activity in vivo. The 
hypothesis is that cigarette smoke inhalation influences Natl and/or Nat2 mRNA and protein 
expression in a tissue specific and/or strain specific manner. 
Methods 
Rat Studies. Male and female rats will be obtained and handled as described under 
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Specific Aim II. Following the 5 day acclimatization period, rats will be exposed to cigarette 
smoke, then immediately sacrificed as described under Specific Aim II. Completion of this aim 
will require a minimum of 48 animals (6 strains X 4 replicates X 2 sexes). 
Smoking Apparatus. A TE-lO fully automated smoking machine connected to two rat 
exposure chambers large enough to hold four cages each (Teague Enterprises, Davis, CA, USA) 
(Teague et aI., 1994) will be utilized to expose rats to smoke from filtered 2R4F research 
cigarettes (Kentucky Tobacco Research and Development Center, University of Kentucky, 
Lexington, KY). This cigarette was developed by the NCI Agricultural Research Service-USDA 
and the Tobacco and Health Research Institute for delivery of approximately 9.2 mg of tar and 
0.8 mg of nicotine. The NCI standard cigarette for experimental work, lR3F, is going out of 
production. The TE-I0 smoking machine holds up to 30 cigarettes which it can automatically 
load, light, puff, and discard. It can smoke up to 10 cigarettes simultaneously at variable flow 
rates, thus providing multiple mechanisms for controlling smoke exposure rates. Chamber air 
flow rates can be monitored and the contents of the air trapped on a filter for easy testing of the 
composition and quantity of chemicals in the chamber air. For each experiment, one chamber 
will be used for smoke exposure (4 rat cages) and the other chamber (4 rat cages) for a control 
environment, with a maximum of four rats per cage. 
Exposure Levels and Times. Rats will be exposed to a single 8 hour smoke exposure 
without a recovery period. In the case that N-acetyltransferases are immediate response genes, 
this time frame should be enough for de novo N-acetyltransferase protein synthesis. The animals 
will then immediately be sacrificed for analysis of the influence of cigarette smoke on Nat 
expression. This large initial exposure is designed to test for any possible influence of cigarette 
smoke inhalation on rat Nat gene expression. If no effect is seen on mRNA levels, protein levels, 
or enzyme activities following the 8 hour exposure, it could be an indicator that cigarette smoke 
exposure does not influence Nat gene expression, or it could indicate that Nats are not immediate 
response genes, and extra time is required for de novo synthesis of transcription factors. If no 
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effect is observed at the mRNA level, a longer exposure (12, 24, 48 hours) or a longer lag time 
between exposure and sacrifice may be necessary to allow time for de novo synthesis of 
transcription factors. 
Determination of Exposure Level and Exposure Effect on Health. Immediately prior 
to exsanguination, a blood sample will be collected from each animal. A commercially available 
enzyme linked immunosorbant assay (ELISA) will be used to measure serum cotinine levels 
(Cozart Biosciences, Ltd, Oxfordshire, UK) as an indication of the smoke exposure of each 
animal. Chamber smoke concentrations will be monitored during each exposure by weighing the 
total filtered suspended particles from a known volume of air over a 5 minute period. Rat weights 
will be recorded before and after exposure as a gauge the general health of the animals. 
Measurement of Tissue mRNA and Protein Expression. The analyses described in the 
previous section ("Specific Aim II") will be followed for analyses of tissue mRNA and protein 
expression in smoke-exposed rats. Since it is up-regulated in response to cigarette smoke 
exposure in rats, CYP1Al mRNA levels will be measured in treated versus untreated rats as a 
control for the effectiveness of our smoke exposure methods. CYP1Al expression will be 
measured by RT-PCR with the primers and probes designed as previously reported (Gebel et aI., 
2004). 
Statistical Analyses. Standard error of the means (SEM) will be calculated for triplicate 
mRNA, protein, and enzyme activity measurements in each tissue from four replicate animals for 
each strain. Likewise, SEM will be calculated to test the variability of mean mRNA expression, 
protein expression, and enzyme activity values for each tissue among four replicate animals. 
Differences in mRNA expression, protein expression, and enzyme activity between treated and 
untreated animals will be tested for significance using a t-test, since only single sets of data will 
be compared. Statistical significance will be determined at values of p < 0.05. 
Potential Additional Analyses and Controls. Microarray analysis of tissue RNA from 
treated and untreated rats could aid in identification of genes with expression altered similarly to 
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Natl and/or Nat2 in response to cigarette smoke components. This type of information could 
provide clues toward determining an endogenous physiological function for Nat in addition to the 
mechanism of Nat regulation (Staudt and Brown, 2000; Le Roch et a\., 2003). This information 
would also validate the methods used here by giving a view of the overall affect of the cigarette 
smoke exposure methods used, enabling comparison of the results to those found in similar 
experiments previously reported in the literature (Gebel et a\., 2004). The Brown Cancer Center 
Microarray Facility provides the equipment and expertise necessary for successful microarray 
experiments. GeneChip Rat Genome 230 2.0 Array (Affymetrix, Inc) provides comprehensive 
coverage of the rat genome, analyzing over 30,000 rat transcripts and variants. 
Potential Setbacks and Alternate Methods. If no differences are detected between the 
Nat] and Nat2 mRNA and protein expression/activity in treated versus untreated rats following 
the initial exposure, we will conclude that cigarette smoke does not influence N-acetyltransferase 
expression/activity in rat. This may provide opportunity to extend the analyses performed in 
Specific Aim II or explore other environmental exposures. 
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